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PERIPHERAL NERVE TISSUE ENGINEERING:  
STRATEGIES FOR REPAIR AND REGENERATION 
Mitra Lavasani, PhD 
University of Pittsburgh, 2008
 
Peripheral nerve injuries are frequently encountered in trauma, sports accidents, military 
activities, and degenerative muscle diseases. Like most neurological conditions, patients exhibit pain, 
sensory and motor deficits, and functional disability. Despite all the advances in biomedical science 
and technology, achieving full function and organ reinnervation after these injuries remains a 
major challenge. High costs of healthcare, loss of employment, and social disruption have 
provided the impetus for active research focusing on improved strategies for repair and 
regeneration. Stem cell therapy holds tremendous potential for the treatment of pathologic 
conditions and has consequently emerged as a new area of focus in regenerative medicine. Stem 
cells isolated from skeletal muscle have been shown to be both pluripotent and of significant 
therapeutic value; however, their ability to undergo neurogenic differentiation has yet to be 
investigated. Here, we report that progenitor cells isolated from skeletal muscles of both mouse 
and human, using our established preplate technique, adopt neuronal and glial phenotypes under 
controlled culture conditions. Transplantation of these cells into a critical-size sciatic nerve 
defect allowed full nerve restoration with induction of axonal regeneration through myelin-
producing Schwann-like cells. Functional recovery resulted in improved gait of cell-transplanted 
mice.  
Multi-lineage progenitor cells have been recently identified in blood vessel walls, notably 
in skeletal muscle, and venous grafts have been used effectively to bridge nerve defects 
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experimentally and clinically, through unknown cellular mechanisms. In a sex-mismatch model, 
we identified donor-derived Y chromosomes co-localized with host Schwann cells’ nuclei, 
indicating nerve repair through vein grafting are mediated by vascular cells. A sustained decrease 
in nerve regeneration by decellularized or irradiated venous grafts also highlights the 
contribution of blood vessel-derived cells to nerve repair. Together, these findings not only 
identify the cellular basis for the efficacy of therapeutic vein wrapping, but also reinforce the 
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1.0  BACKGROUND 
1.1 ORGANIZATION OF THE NERVOUS SYSTEM 
The nervous system is classified into the central nervous system (CNS) and the peripheral 
nervous system (PNS). The CNS, which includes the brain, spinal cord, optic, and olfactory and 
auditory systems, conducts and interprets signals as well as provides excitatory stimuli to the 
PNS. The PNS consists of the cranial nerves arising from the brain, the spinal nerves arising 
from the spinal cord, and sensory nerve cell bodies (dorsal root ganglia) and their processes. 
Peripheral nerves innervate muscle tissue, transmitting sensory and excitatory input to and from 
the spinal column. 
1.2 CELLULAR COMPONENTS OF THE NERVOUS SYSTEM  
The nervous system is composed of two cell types: neurons and neuroglia. Neurons are the basic 
structural and functional elements of the nervous system and consist of a cell body (soma) and its 
extensions (axons and dendrites). Clusters of sensory nerve soma, known as ganglia, are located 
just outside the spinal column. Dendrites transmit electrical signals to the neuron cell body and 
the axon conducts impulses away. Glial cells, or neuroglia, are support cells that aid the function 
of neurons and include Schwann cells in the PNS and astrocytes and oligodendrocytes in the 
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CNS. Glial cells are more abundant than neurons, and undergo mitosis (cell division) when 
needed. Unlike neurons, glial cells do not conduct electrical impulses [1]. 
In the PNS, many axons are surrounded by an insulating myelin sheath formed from 
multiple layers of successive wrappings of the cell membrane of specialized living cells called 
Schwann cells (PNS) or oligodendrocytes (CNS). Myelin serves to increase the propagation 
velocity of the nerve impulse (action potential), which is particularly important for those axons 
in PNS that extend long distances [1, 2]. These motor neurons relay messages from brain or 
spinal cord to the muscles and organs and can be over 1 meter long (Figure 1.1). Action 




Figure 1.1:  Motor neuron with myelinated axon  
A typical motor neuron has few processes called dendrites which extend out from the cell body and 
branch out extensively. It also has a long fibrous axon which originates from a somewhat thickened area 
of the cell body. A short distance from its origin, the axon acquires a sheath of myelin, a protein- lipid 
complex made up of many layers of unit membrane. The myelin sheath envelopes the axon except at its 
ending and at periodic constrictions about 1mm apart called nodes of Ranvier. The axon ends in a number 
of synaptic knobs at motor end plates. (Figure adapted from www.biologymad.com). 
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1.3 ANATOMY OF THE PERIPHERAL NERVE  
A peripheral nerve consists of motor and sensory axons bundled together by support tissue into 
an anatomically defined nerve trunk (Figure 1.2). In myelinated axons, a single Schwann cell 
provides insulation to only one axon, while in unmyelinated axons, one Schwann cell envelops 
several axons [1, 2]. Endoneurium surrounds individual axons and their Schwann cell sheaths 
and is composed predominantly of oriented collagen fibers. Next, the perineurium, formed from 
many layers of flattened cells (i.e., fibroblasts) and collagen, surrounds groups of axons to form 
fascicles. Finally, epineurium, an outer sheath of loose fibrocollagenous tissue, binds individual 
nerve fascicles into a nerve trunk. Peripheral nerves are well vascularized by capillaries within 
the support tissue of the nerve trunk or by vessels that penetrate the nerve from surrounding 




Figure 1.2: Anatomical overview of the PNS 
Axons, surrounded by myelinated Schwann cell sheaths, are enclosed by endoneurium. Next, the 
perineurium binds individual axons together to form fascicles. Several axons are contained in each 
fascicle. Lastly, epineurium groups fascicles to one another, forming the nerve cable. (Figure adapted 
from www.backpain.guide.com/Chapter 10-1/Internal Structure of Peripheral Nerves). 
1.4 PERIPHERAL NERVOUS SYSTEM INJURY 
The most severe injury is a complete nerve transection. When the axon is disconnected from the 
cell body by injury, its distal segment and myelin sheath gradually degenerates, a feature known 
as Wallerian degeneration (Figure 1.3). As the degeneration of the distal nerve segment 
continues, connection with the target organ such as muscle is lost, leading to muscle atrophy and 
fibrosis. The early phase of the degeneration process includes the breakdown of the cytoskeleton, 
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dissolution of the cell membrane, and the Schwann cells surrounding the axons shedding off 
their myelin lipids. The proximal end of the nerve stump starts to swell but experiences only 
minimal damage via retrograde degradation (Figure 1.3, Step 1). After the cytoskeleton and 
membrane degradation, phagocytic macrophages and Schwann cells remove myelin and axonal 
debris [4] and produce cytokines, which enhance axonal growth [5] (Figure 1.3, Step 2). 
Schwann cells proliferate in the distal nerve segment and when contacted by an axon sprout, 
undergo a cascade of changes that trigger the production of myelin [6] and form a cell strand 
called Schwann cell column or band of Büngner [7]. These bands, together with the basal lamina 
sleeve that surrounds them, guide regrowing axons toward their original innervation [8-15]. 
Following debris clearance, regeneration begins at the proximal end by the Schwann cells and 
continues toward the distal stump by phenomenon known as chemotaxis (tropism) [16, 17]. 
Activation of Schwann cells occurs as early as 12 hours after injury [17]. New axonal sprouts 
with a fingerlike growth cone usually emanate from nonmyelinated areas of axons called the 
nodes of Ranvier, located between Schwann cells, and advance using Schwann cells as guides 
(Figure 1.3, Step 3). Conduction of action potentials only occurs at the nodes; this is called 
saltatory conduction. This mechanism increases the velocity of nerve as much as 5-fold to 50-
fold (up to 200 meters per second) and explains the speed at which we can react to potentially 
harmful stimuli [2]. These sprouts are thinly myelinated by numerous new, but smaller Schwann 
cells, due to the very limited amount of amino acids produced by the cells at this stage [17] 
(Figure 1.3, Step 4). Functional reinnervation requires that these axons extend until they reach 
their distal target and the target organ (e.g. skeletal muscle), this usually takes a long period of 
time (2-5 mm/day in human), and significant injuries can take many months to heal [18].  
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 Figure 1.3: Illustrations showing the Wallerian degeneration of the peripheral nerve. 
After significant injury, the axon and surrounding myelin break down. (b) Schwann cells form a solid 
cellular core along the axonal path to unite the stumps while releasing many growth factors, and 
Macrophages engulf degenerated axon and myelin. (c) Axon send buds into network of Schwann cells 
and advance along cord of Schwann cells using it as a guide. (d) Axon continues to grow into distal stump 
and is enfolded by Schwann cells. The newly connected axon to the target organ matures and the pre-
injury and the tissue architecture and function are restored. Figure adopted and modified from 
www.biomed.metu.edu. 
 
1.5 CURRENT TREAMENTS AND THEIR CHALLANGES  
For peripheral nerve injury, treatment typically consists of either direct end-to-end surgical 
reconnection of the damaged nerve ends or the use of an autologous nerve graft. Suturing the 
ends of the two nerve ends together can repair small defects or gaps in the nerve. For longer 
nerve gaps, this approach is not desired because any tension introduced into the nerve cable 
would inhibit nerve regeneration [19]. Thus, for a larger nerve defect, an autologous nerve graft 
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that is harvested from another site in the body is used to span the injury site [20, 21]. 
Disadvantages of this technique include loss of function at the donor site and the need for 
multiple surgeries. Bioengineering strategies for the PNS have focused on developing alternative 
treatments to the nerve graft (e.g., nerve guidance channels and vein grafts), especially for larger 
defects, and improving recovery rates and functional outcome. These challenges provide fertile 
ground for the development of therapies to enhance regeneration.  
1.5.1 Guidance therapies 
Physical guidance of axons is a vital component of nerve repair. During the nineteenth century, 
many materials were used in an attempt to physically guide the regeneration of damaged 
peripheral nerves, including autologous nerve grafts [22], bone [23], metal tubes [24], and fat 
sheaths [25]. It was not until the 1960s that Millesi pioneered microsurgical techniques to 
accurately align nerve fascicles in the direct resection of nerve ends, with improved functional 
outcomes [19]. He also determined that the use of nerve grafts reduced tension on the damaged 
nerves in many cases and further enhanced functional recovery. These results also supported the 
need for physical guidance as an essential element in nerve regeneration. Later research 
demonstrated that biochemical signals as well as physical guidance are critical for nerve 
regeneration [26-29]. Current research is focused on developing improved “nerve guides” or 
“nerve conduits” that can be used to physically guide regeneration of nerves across lesions. Past 
research in this area has focused either on existing natural or synthetic materials; however, none 
of the materials studied to date have matched or exceeded the performance of the nerve 
autograft. As a result, researchers are now focusing on the combination of materials and desired 
biomolecules to create new composite materials that can actively stimulate nerve regeneration. In 
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addition, methods to minimize the immune response to nonautologous tissue could provide a 
source of natural material for nerve repair. 
1.5.1.1 Autologous tissue grafts 
The employment of an autologous nerve segment as an autograft was first reported in 
1878, but used widely during World War II [30, 31] and became a standard technique for 
repairing nerve gaps since the 1970s [32]. For a more thorough synopsis of the early history of 
nerve repair using nerve grafts, refer to the review by Chiu et al. [33]. For additional information 
on the surgical techniques used in nerve grafting see references [21, 34-37]. Natural materials are 
more likely to be biocompatible than artificial materials, are less toxic, and provide a support 
structure to promote cell adhesion and migration. However, this technique is limited as it entails 
the sacrificing of healthy donor tissue, the need for multiple surgical procedures, and possible 
formation of painful neuroma (a bulb-shaped thickening created by improperly and irregularly 
regenerating nerve fibers). These significant drawbacks have prompted a search for alternative 
types of non-nervous tissue-engineered guides for repairing nerve defects that could serve to 
direct axons sprouting from the proximal to the distal end, provide a conduit for the diffusion of 
growth factors secreted by the injured nerve ends to facilitate restoration, reduce the infiltration 
of scar tissue, reduce denervation-induced atrophy of muscles, and minimize pain.  
In addition to the nerve graft, other natural tissues, such as autologous muscle [38, 39] 
and vein grafts [33, 40-42], have been used in the clinic. Furthermore, some current research 
efforts are focused on natural tissue grafts for peripheral nerve repair, including the use of 
epineurial sheaths [43], tendon grafts [44], muscle-vein combined grafts [45, 46], inside-out vein 
grafts [47], and vein grafts impregnated with autologous Schwann cells [48]. All have exhibited 
encouraging results in research but still suffer from the key drawback that tissue must be 
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removed from the patient. Moreover, veins may also collapse especially when bridging long gaps 
because of their thin wall and absence of pressure from inside, while the surrounding scar tissue 
can cause constriction. Using the combined muscle-vein technique has helped to prevent 
collapsing of the vein wall, but the nerve fibers can easily divert from the muscle tissue and form 
neuroma in continuity.  
1.5.1.2 Non-autologous tissue grafts 
Other natural tissues including small intestinal submucosa (SIS) and amniotic tissue 
grafts have been explored for nerve repair applications. SIS is an acellular matrix derived from 
small intestine, typically of porcine origin. SIS is prepared from the mucosa and muscle layers of 
the small intestine, which are treated with a hypotonic solution to lyse and wash away the cells. 
The resultant ECM material is composed of collagen, fibronectin, growth factors, 
glycosaminoglycans, proteoglycans, and glycoproteins [49, 50]. Recently, SIS derived from rats 
has been used in conjunction with Schwann cells to create nerve grafts that promote regeneration 
almost as well as the nerve autograft [51]. 
Amnion harvested from human placental tissues has also received attention for its 
potential use in nerve regeneration applications [52-57]. The amnion is a natural, biodegradable 
tissue that exhibits low immunogenicity and stimulates new vascularization [58]. This material is 
also readily available and does not require surgical procedures for harvesting. This tissue is 
processed by removal of the epithelial cell layer from the amnion membrane while the basement 
membrane and stromal surfaces remain intact. The resulting acellular connective tissue matrix 
are manufactured into thin dry sheets and then subsequently processed into conduits. 
Comparable to the nerve autograft, amnion tubes have been shown to promote regeneration 
across 1 cm defects in the sciatic nerves of rats, and completely degrade by 4 months [54]. 
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1.5.1.3 Synthetic materials 
Research is growing to identify synthetic materials that can be used for nerve repair 
applications. The earliest of these was made of silicone. However, this non-biodegradable 
material eventually produces nerve constriction resulting in pain and partial destruction of the 
regenerated axons [59]; for this and other reasons, the focus of the search was shifted to nerve 
guides composed of biodegradable material. Biodegradable natural materials such as collagen, 
fibronectin, and laminin, as well as biodegradable synthetic materials such as polyesters, 
polyurethanes, and poly (organo) phosphazenes, have all been investigated as autograft 
substitutes. All of these materials can be used to provide a scaffold for axonal regeneration but 
lack the ability to actively stimulate nerve regeneration with the support cells and neurotrophic 
factors found in autologous grafts. For this reason, simple nerve guides have been effective only 
for short defects and are therefore of limited value in clinical practice particularly for large nerve 
defects [60-62]. But, synthetic materials are still attractive choice because their chemical and 
physical properties (e.g., degradation rate, porosity, mechanical strength) can be specifically 
optimized for a particular application.  
According to Hudson et al. [63], the desired physical properties of a nerve guidance 
channels include: a biodegradable and porous channel wall (to allow diffusion of nutrients and 
elimination of waste products); the ability to deliver bioactive factors such as growth factors; the 
incorporation of support cells; an internal oriented matrix to support cell migration; intraluminal 
channels to mimic the structure of nerve fascicles; and electrical activity. For detail reviews of 
different synthetic materials used in aiding nerve regeneration refer to review paper by Hudson 
and Schmidt [63]. Despite the combined efforts of scientists and engineers from a variety of 
disciplines to design sophisticated synthetic nerve guides, the outcome after peripheral nerve 
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repair has not been satisfactory. Functional recovery is not always obtained, reinnervation may 
be unsatisfactory, and neuroma and scar tissue formation are common. In addition, the 
biocompatibility of synthetic materials poses a challenge because of inflammatory response 
causing immunorejection. More research is required to discover synthetic materials that are 
tolerated by the immune system and are more “cell friendly” in order to achieve functional 
recovery of peripheral nerve through combined therapies. 
1.5.2 Cellular therapies 
Independently of the type of non-nervous conduit employed to bridge a nerve gap, it was soon 
became clear to researchers that the availability of an adequate number of Schwann cells along 
the entire graft length to support axon regeneration was the critical point, as judged by the 
eventual success of the nerve repair. In fact, when non-nervous guides are used, Schwann cells 
that are required for successful axon regeneration inside the tube originate from bilateral 
migration from both severed nerve stumps [12, 64-67]. Consequently, there has been growing 
enthusiasm for the use of cell-based therapies for peripheral nerve regeneration. This concept is 
based upon the ability of transplanted cells to differentiate into specific tissue cell types or 
participate in the recovery process by cell fusion and/or differentiation, cell-to-cell contact, or 
sustained release of neurotrophic factors. These properties may be the premise of an early 
regenerative stage that leads to accurate target reinnervation, and, thus, less axonal dieback. 
1.5.2.1 Schwann cells 
Schwann cells are prime providers of the supportive environmental milieu for peripheral 
nerve tissue, as they produce neurotrophic factors, neural adhesion molecules, and extracellular 
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matrix proteins [68, 69]. These cells play a critical role in leading peripheral axons to the distal 
nerve stump and synapse formation [70], and are consequently integral to peripheral nerve 
regeneration [71]. Nerve grafts without viable Schwann cells have shown an inferior axonal 
regeneration caused by a decrease in neurotrophic and neurotrophic influence [72, 73]. For all of 
these reasons, the ability of Schwann cells to promote nerve regeneration has been a research 
area of intense focus [74-77]. There are two major difficulties in using Schwann cells for nerve 
guides in clinical situations. First, autologous Schwann cells need to be harvested from the 
injured patient, requiring nerve tissue that is difficult to obtain without morbidity. Second, 
human Schwann cells are difficult to isolate and expand in vitro, requiring elaborate mitogenic 
cocktails and prolonged periods of growth to obtain sufficient cultures for nerve guide 
construction. These difficulties significantly limit the clinical feasibility of a nerve guide 
containing autologous Schwann cells. Therefore, researchers continue to pursue the development 
of cellular therapies based on populations of stem cells capable of Schwann cell differentiation. 
1.5.2.2 Stem cells 
Stem cells play a critical role during embryo and tissue formation throughout 
development. Due to their multipotentiality, the ability to give rise to different lineages of mature 
cells, and to an extensive capacity for self-renewal and expansive growth, stem cells can also 
contribute to the maintenance of tissue integrity in adulthood. Historically, it has been held that 
fetal and adult (somatic) stem cells are tissue-specific 'entities' whose differentiation potential is 
limited to the generation of mature cell types of the tissue/organ in which they reside. Yet, recent 
years have seen the publication of an impressive sequence of reports detailing what is now 
emerging as one of the most striking functional attributes of somatic stem cells, the capacity to 
undergo transdifferentiation. This peculiar characteristic allows adult stem cells to display an 
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unexpected ability to give rise to differentiated cells of tissues and organs different from those in 
which they reside.  
It is postulated that adult stem cells may provide promise for improving functional 
outcomes after peripheral nerve injuries by a combination of many factors. Stem cells can act as 
surrogate Schwann cells and supply neurotrophic factors and cell adhesion molecules to aid 
axonal outgrowth over long distances, prevent degeneration of distal ends, restore growth-
promoting ability via differentiation toward glial cells (especially Schwann cells), and deliver 
supportive ECM components [78]. The utility of stem cell therapy is based on variety of their 
unique characteristics and behaviors: (i) self-renewal that results in a large number of progeny; 
(ii) long-term proliferation while in a transient quiescent state; and, (iii) multilineage 
differentiation that increases the efficiency of transplanted stem cells to differentiate into tissue-
specific cell types.  
Research in the use of adult-derived stem cells for regenerative medicine is rapidly 
progressing. Post-natal cells can circumvent some of the problems associated with embryonic 
stem cells, such as immunologic incompatibility, and ethical issues. Recent investigations have 
clearly demonstrated that multiple types of pluripotent stem cells exist in various types of 
postnatal tissues [79-83]. Neural stem cells, which are imprinted to generate neurons and glial 
cells, can differentiate into blood [84] and skeletal muscle cells [81, 82] as well as give rise to 
cell types found in all germ layers when implanted within the amniotic cavity of chick embryos 
[81]. Bone marrow stem cells, which are mainly destined to replenish blood cell populations, can 
contribute to the formation of various cell types in skeletal muscle [79, 80], the liver [85], and 
the brain [83, 86-89]. However, recent studies have called into question the observations of bone 
marrow cells dedifferentiation into neurons [90, 91]. Adipose-derived stem cells from mice and 
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human have also been shown to undergo osteogenic, myogenic, chondrogenic, and neurogenic 
differentiation [92-100]; for review papers refer to Kokai et al., and Safford et al. [101, 102].  
Skin-derived precursors can proliferate and differentiate in culture to produce neurons, 
glial, smooth muscle cells, and adipocytes [103]. Hair follicle stem cells have been shown to 
differentiate into neurons, glial, keratinocytes, smooth muscle cells, and melanocytes in vitro 
[104] and contributed in regeneration of severed peripheral nerve by differentiation toward 
Schwann cells [105]. Together, these studies indicate that different tissues contain a small 
population of pluripotent stem cells with the capacity to generate the tissue in which they reside 
and the ability to differentiate into diverse lineages when stimulated by appropriate 
environmental cues. Therefore, stem cells are being extensively investigated as transplants to 
support nerve regeneration. 
1.6 STEM CELLS AND THEIR MICROENVIRONMENTAL NICHE: AN 
INSEPARABLE RELATIONSHIP 
The concept of a niche as a specialized microenvironment housing stem cells was first proposed 
by Schofield almost 30 years ago in reference to mammalian haematology [106]. In the 
respective organs, tissue-specific stem cells are often localized in specific compartments (termed 
stem cell niches) where they are provided with the environmental requirements for their 
proliferation and differentiation [107]. The simple location of stem cells is not sufficient to 
define a niche. The niche is both anatomically and functionally dimensioned, specifically 
enabling stem cells to reproduce and self-renew [108]. The survival, expansion and 
differentiation of stem cells appear to be regulated by environmental signals as well as potential 
 14 
of the cells themselves [109-111]. Different growth factors, cytokines, extracellular matrix 
proteins, and neurotransmitter have been implicated in the epigenetic regulation of the 
proliferation and differentiation processes [112-115]. Because cell fate conversion occurs when 
stem cells are transplanted to different environments, it has been proposed that stem cells are 
extremely plastic and have the ability to respond to various environmental signals that regulate 
their change in commitment. This cell fate conversion or trans-differentiation capacity of stem 
cells represents an emerging and promising area of study because of its therapeutic implications 
(for reviews refer to [107, 116]. Perhaps the niche may become a guide to novel way to enhance 
the regenerative capacity of normal stem cells and limit the malignant potential of cancerous 
ones. This interplay between stem cells and their niches may create the dynamic system 
necessary for sustaining tissues, and for the ultimate design of stem-cell therapeutics or anti-
cancer drugs.  
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2.0  SIGNIFICANCE  
Each year, over 50,000 peripheral nerve repair procedures are performed in the United States 
(National Center for Health Statistics based on Classification of Diseases, Ninth Revision; 
Clinical Modification for ICD-9 CM codes 04.3, 04.5, 04.6) due to physical injuries, systemic 
diseases, and inherited peripheral neuropathies. Peripheral nerve injuries are commonly 
encountered clinical problems that often lead to long-term functional deficits and expensive 
health care, lost employment, and social disruption [117]. Patients with peripheral nerve 
problems, like most neurological conditions, exhibit pain, sensory and motor deficit due to loss 
of axonal continuity, and functional disability.  
Despite recent advances in microsurgical techniques and improved understanding of 
nerve regeneration, functional recovery following repair of peripheral nerves often remains poor 
[118, 119] due to many factors: (i) a progressive decline in the ability of motor neurons to sustain 
axonal growth; (ii) denervated Schwann cell atrophy and failure to provide a supportive growth 
environment; (iii) slow rate of axonal regeneration across the gap; (iv) misdirection of 
regenerating axons due to random reinnervation; and, (v) the formation of painful neuroma [16]. 
Therefore, achieving full function and accurate reinnervation after these injuries continues to be 
a major challenge. These consequently exacerbated burdens on patients and society have 
provided the impetus for research into reconstructive strategies for repairing peripheral nerve 
injuries.  
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2.1 SKELETAL MUSCLE-DERIVED STEM CELLS: POTENTIAL CANDIDATE 
FOR TISSUE ENGINEERING 
In 1993, Langer and Vacanti [120] defined tissue engineering as “an interdisciplinary field that 
applies the principles of engineering and life sciences toward the development of biological 
substitutes that restore, maintain, or improve tissue or organ function.” Tissue engineering has 
now emerged as a potential alternative to tissue or organ transplantation and stem cell therapy 
emerged as an area of focus in regenerative medicine. Cells play a key in tissue engineering and 
repair due to active participation by proliferation and differentiation, cell-to-cell signaling, 
biomolecule production, and formation of extracellular matrix, or indirect contribution by 
triggering the recruitment and activation of the host cells at the site of injury vital to aiding the 
process of regeneration. Skeletal muscle is as an accessible source from which somatic stem cells 
with the capacity to undergo multilineage differentiation could be isolated for utilization in cell 
replacement therapies [80, 121-127]. Muscle-derived stem cells (MDSCs) isolated from skeletal 
muscle by a modified preplate technique have been recognized by the Huard group for sustained 
self-renewal and proliferation, plasticity, and most recently resistance to oxidative/hypoxic stress 
[124, 128-130]. MDSCs differentiate into several cell types, including skeletal muscle, 
osteogenic, hematopoietic, and vascular endothelial cells [122, 124, 127]. Furthermore, MDSCs 
have been used to regenerate skeletal and cardiac muscle as well as bone and cartilage in vivo, 
and to replenish the bone marrow of lethally-irradiated mice [122, 124, 131, 132]. 
MDSCs can be an attractive candidate for clinical use in regenerative medicine because 
they can be easily obtained by a relatively non-invasive superficial muscle biopsy, readily 
expanded in vitro, and transplanted in an autologous manner. Following transplantation, MDSC 
most likely enhance restoration of damaged tissue by differentiation toward the necessary 
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lineages and secreting trophic factors. In case of neuronal tissue engineering, we desire these 
cells to restore the neural and vascular supply during nerve regeneration by undergoing 
multipotent differentiation into endothelial, neural and Schwann cell-like phenotypes, the 
primary types of tissue required for proper nerve healing. Furthermore, the application of 
exogenous neurotrophic factors by MDSCs could be an effective means of promoting 
regeneration in an ex vivo gene therapy approach to deliver therapeutic factors that would 
enhance the effect of cell transplantation. Transplanted MDSCs pose advantages as a means of 
delivering a continual supply of active neurotrophins [133], which promote the recruitment of 
macrophages and Schwann cells at the site of injury, thereby facilitating more active and directed 
axonal growth and promoting regeneration. They may also contribute by differentiating toward a 
neuronal/glial lineage themselves.  
2.2 PROJECT OBJECTIVES 
The overall objective of this research project is to determine the potential of murine muscle-
derived stem cells (mMDSCs) and human muscle-derived progenitor cells (hMDPCs) isolated 
via the modified preplate technique to adopt neuronal and glial (in particular Schwann cell) 
phenotypes in vitro, and examine the capacity to support peripheral nerve regeneration and 
remyelination in vivo. In addition, cellular mechanism behind the efficacy of vein grafts applied 
as nerve conduits in clinic is also investigated. The objectives outlined below will help to test our 
hypotheses at all three levels: histological, biochemical, and functional.  
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2.2.1 Objective 1: Investigation of mMDSCs to adopt neuronal and glial phenotypes, and 
regenerate peripheral nerve defects 
Our group has previously shown that cultured mMDSCs can differentiate toward skeletal 
muscle, bone, cartilage, endothelial, and hematopoietic cell lineages [122, 124, 127, 131, 132]. 
However, their capacity for neuronal and glial differentiation is unknown. It has been postulated 
that the microenvironment dictates the fate of stem cells, therefore we hypothesized that 
mMDSCs undergo mature neuronal and glial lineages differentiation under controlled culture 
conditions. Also, transplantation of mMDSCs accelerates the regeneration and functional 
recovery of critically sized sciatic nerve defects in mice following injury. The expression level of 
a population of mMDSCs for mature neuronal and glial-specific cell markers was screened in 
pre- and post-differentiation culture conditions, by means of immunocytochemical staining.  
Additionally, the process of nerve regeneration, including the proper regeneration and degree of 
myelination, as well as mMDSCs contribution through differentiation, was evaluated by 
histology, immunohistochemistry, and electron microscopy. Functional recovery of the severed 
sciatic nerve was determined using walking track assessment to evaluate nerve to muscle 
reinnervation.  
 
2.2.2 Objective 2: Evaluation of hMDPCs for neuronal and glial differentiation, and 
nerve regeneration capacity  
There is growing evidence to suggest that reservoirs of stem cells may reside in human skeletal 
muscle that can retain the potential to transdifferentiate from one phenotype to another, 
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presenting exciting possibilities for cellular therapies. The optimal cell type for neural tissue 
engineering would be progenitor/stem cells that survive, migrate, and engraft to promote 
regeneration. We hypothesized that hMDPCs isolated using our established modified preplate 
technique are capable of neuronal and glial differentiation. In addition, transplantation of these 
cells will improve the regeneration and functional recovery of critically sized sciatic nerve 
defects following injury.  
Under controlled cultural conditions, we evaluated the capacity of hMDPCs to adopt 
neuron, astrocytes, oligodendrocytes, and Schwann cell phenotypes. Our proposed stem cell-
based therapy relied on the ability of transplanted hMDPCs to facilitating the axonal 
regeneration, remyelination, and reduction of neuroma formation in our murine sciatic nerve 
defect model. Hence, the efficacy in achieving sciatic nerve regeneration following hMDPCs 
implantation was evaluated quantitatively by assessing motor function and improvement of gait 
as well as histological characterization of the regenerated nerve. The data generated from these 
experiments will further elucidate multipotentiality of hMDPCs and may help facilitate their 
usage potential candidate in cell-mediated therapies and tissue engineering applications for 
peripheral nerve injuries. 
2.2.3 Objective 3: To identify cellular mechanisms for the efficacy of venous grafts in 
peripheral nerve reconstruction   
Venous grafts are used experimentally and clinically to bridge peripheral nerve defects. This 
alternative strategy rely on the fact that the donor vein is easily withdrawn in close proximity to 
the involve nerve with minimal complications eliminating the sacrifice of healthy nerve. This 
approach has been highly conducive to tissue regeneration, and shows great promise for repair of 
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damaged nerves. However, exactly why vein wrapping or the use of venous nerve conduits is so 
successful in regenerating peripheral nerve is a question that remains, as yet, unanswered. In 
addition, a recent study has identified endothelial cells as critical components of the neural stem 
cell niche and their self-renewal [134]. A novel subset of cells overlapping phenotype between 
myogenic and endothelial cells was recently reported by our group to exhibit strong myogenic 
potential in skeletal muscle [135]. Interestingly, human endothelial cells and vascular pericytes 
were recently documented to be capable of generating various mesodermal derivatives, primarily 
skeletal muscle [136]. These results let us postulate that blood vessels may harbor a reserve of 
multi-lineage stem cells that play an active role in the process of regeneration.  
Therefore, we hypothesized that venous nerve guides might improve healing of 
peripheral nerve defects due to contribution of stem/progenitor cells that reside in donor blood 
vessels. This may elucidate the rationale behind efficacy of using venous nerve conduits in 
surgical procedures to bridge peripheral nerve damage. Hence, we aimed to investigate this 
underlying principle by using a rat sex mismatch model and fluorescence in situ hybridization to 
detect donor-derived Y chromosomes in regions of host regenerated nerve. In doing so, we may 
uncover useful information to explain the cellular basis for the success of such clinical 
treatments, and provide the cornerstone for future work intended to explore the relationship 
between stem/progenitor cells, cell differentiation and/or fusion, and nerve regeneration.  
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3.0  FATE OF MDSCS IS MICROENVIRONMENT DEPENDENT  
3.1 INTRODUCTION 
Cell-to-cell interaction, cell-to-tissue matrix contact, and the presence of certain factors and 
signaling molecules together within the stem cell niche/compartment regulate stem cell 
homeostasis and determine their fate [137, 138].  Stem cells are engaged in constant cross-talk 
with their environment, and are influenced by the signals that they receive [137]. In 1968, 
investigators revealed that bone marrow possessed unique and potent attributes; hematopoietic 
stem cells (HSCs) that resided there appeared to be able to live forever. Once HSCs left the 
marrow environment, the cells immediately began to differentiate [139]. It has consequently 
been suggested that the environment is a greater factor in neural stem cell fate than the intrinsic 
properties of the cell [140]. More and more researchers are embracing the ecological concept of 
the niche and have begun to equate niche with the microenvironment in which the stem cells 
reside. Hence, it is believed that the interplay between stem cells and their niche creates key fate-
determining events necessary for sustaining tissues [108, 141]. 
Muscle-derived stem cells (MDSCs) isolated from the skeletal muscle of normal mice 
(mMDSCs) have been recognized by our group for their sustained self-renewal and proliferation, 
developmental plasticity, and most recently resistance to oxidative/hypoxic stress [124, 128, 
129]. Cultured MDSCs can differentiate into several cell types, including skeletal muscle, 
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osteogenic, hematopoietic, and vascular endothelial cells [122, 124, 127]. Furthermore, we have 
used these cells to regenerate skeletal and cardiac muscles as well as bone and cartilage, and to 
replenish the bone marrow of lethally-irradiated mice [122, 124, 131, 132]. Prior studies in our 
laboratory have also examined the roles of bone morphogenetic protein (BMP)4, nerve growth 
factor (NGF), and vascular endothelial growth factor (VEGF) on MDSCs fate [122, 124, 133]. 
Namely BMP4 induced osteogenesis [122], while NGF and VEGF induced neurogenic and 
endothelial differentiation of MDSCs [122, 124]. In addition, NGF stimulation of MDSCs 
significantly improved their engraftment in dystrophic muscles of mdx mice [133], suggesting a 
link between neurogenesis and myogenesis, and substantiating the role of the environment in 
stem cell differentiation. However, the potential involvement of mMDSCs in neurogenesis 
remains undetermined. The objective of this study was to investigate differentiation ability of 
mMDSCs toward neuronal and glial cell lineages in culture, and explore their regeneration 
efficiency in vivo using a sciatic nerve defect model in mice. 
3.2 RESULTS 
3.2.1 Myogenic differentiation 
3.2.1.1 FNr-MDSCs display stable cell marker profile  
Using a modified preplate technique, we have previously isolated MDSCs from wild-type 
skeletal muscle according to their adhesion and proliferation characteristics [122, 124, 142]. 
MDSCs differentiate to multiple cell lineages in vitro and in vivo [124, 127]. We employed this 
technique on skeletal muscle from a female newborn (FN) C57BL/10J mouse to isolate FN-
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MDSCs. Similar to previously reported isolates [124], most of these cells were positive for the 
stem cell surface markers CD34 (88.5%) and Sca-1 (87%), showing 78% CD34/Sca-1 double-
positive cells by flow cytometry, and very few cells expressed myogenic cell marker desmin 
(<1.5%), as observed following immunofluorescence staining. The cells were initially plated at a 
density of 250 cells/cm2 and 20-30% confluency, and transduced with a retroviral vector 
containing a nuclear LacZ reporter gene (nLacZ) [122, 124, 131] for donor cell tracking. The 
cells were subcloned to obtain a population (FNr-MDSCs) that was over 90% ß-gal-positive 
(Figure 3.1a). We found no significant difference in cell marker expression compared to the 
parental FN-MDSCs, suggesting the stability of FNr-MDSCs in vitro.  
3.2.1.2 FNr-MDSCs display a high myogenic potential in vitro and in vivo 
As it has been previously reported that MDSCs generally have a high myogenic index 
[122, 124], the ability of FNr-MDSCs to undergo myogenesis was assessed. FNr-MDSCs were 
cultured in myogenic differentiation medium (2% FBS in DMEM) for 5 days. After cultivating 
the cells under low-serum conditions, myotube formation was detected by immunocytochemical 
staining for expression of fast myosin heavy chain (f-MyHC), a marker of terminal myogenic 
differentiation. As expected, FNr-MDSCs fused and formed multinucleated myotubes expressing 
f-MyHC (Figure 3.1b). Myogenic potential of FNr-MDSCs was further evaluated by their 
ability to regenerate dystrophin-positive muscle fibers after intramuscular implantation in 
dystrophin-deficient mdx mice was examined. Fourteen days post-implantation, many 
dystrophin-positive myofibers could be found within the injected muscle (n = 10; three 
independent experiments, Figure 3.1c). Furthermore, donor-derived nLacZ-positive nuclei could 





Figure 3.1: FNr-MDSCs exhibit myogenic differentiation potential in vitro and in vivo 
(a) A population of female newborn MDSCs (FN-MDSCs) was genetically engineered to express a 
retroviral vector containing a nuclear LacZ reporter gene (nLacZ). Positive staining (blue) is localized to 
the nucleus of the cells. (b) Ten days after culture in low serum differentiation medium, FNr-MDSCs 
differentiated into multinucleated myotubes expressing f-MyHC (red) (overlaid on nuclear counterstain 
[DAPI; blue]). (c) Fourteen days after injection, cryosections of the gastrocnemius muscle of mdx mice 
immunostained for dystrophin expression show large numbers of regenerated dystrophin-positive 
myofibers (red). (d) The nLacZ-positive donor-derived FNr-MDSCs (blue) could be detected in 
regenerated myofibers 17 weeks after injections. Scale bars represent 100 μm. 
 
3.2.2 Neuronal and glial cell differentiation 
3.2.2.1 FNr-MDSCs express both neuronal and glial cell markers and can undergo 
neuronal and glial differentiation in vitro  
Though MDSCs are myogenic both in vitro and in vivo [122, 124], the purpose of this 
work was to ascertain the potential involvement of MDSCs in neurogenesis. FNr-MDSCs were 
screened by immunocytochemistry for a series of neurogenic and glial cell markers prior to 
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differentiation. Most undifferentiated FNr-MDSCs (96% ± 4.9) were positive for nestin (a 
neuroepithelial progenitor marker), CNPase, a marker of oligodendrocytes (88% ± 9.0), and 53% 
± 14.0 positive for neurofilament (NF, a postmitotic neuronal cell marker); but negative for other 
cell markers of neuronal maturity, such as neuronal nuclei (Neu-N), suggesting the phenotypic 
heterogeneity of FNr-MDSCs. In defined serum-free medium supplemented with growth factors 
(EGF and bFGF) [125], FNr-MDSCs generated free-floating clusters of cells (FNr-MDSC-
derived neurospheres) within 7 to 10 days (Figure 3.2a, bright-field) with many cells on the 
outer surface displaying microspikes; a characteristic of neurospheres evident at higher 
magnification [125]. These clusters were successfully passaged and expanded as single cell 
suspension. Three to five days after each passage, all cells formed neurospheres. These FNr-
MDSC-derived neurospheres expressed neuronal markers (β-tubulin III, NF, and Neu-N), a 
marker for myelin producing oligodendrocytes and Schwann cells (CNPase), and the astrocytic 
marker, glial fibrillary acidic protein (GFAP) (Figure 3.2a). Though FNr-MDSC-derived 
neurospheres expressed lineage commitment markers, the expression of neuroendothelial 
progenitor marker nestin was also retained (Figure 3.2a).  
The FNr-MDSCs, unlike some neural stem cells derived from the developing brain [143], 
appear to require exogenous factors to trigger commitment to a neurogenic cell lineage. 
Elimination of mitogens, a negatively charged surface (poly-D-lysine), and high serum levels 
(10% FBS) were required to induce further neuronal and glial differentiation of our adult stem 
cells. After 3 days in differentiation medium, FNr-MDSC-derived neurospheres induced cells 
with diverse morphology, including small and round, large and flat, spindle-shaped cells, and 
round cell bodies with thin extended processes (Figure 3.2b, bright-field). Over 70% of cells 
were positive for the neuronal markers β-tubulin (Figure 3.2b, N) and NF, and 88% were 
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positive for the astrocyte marker GFAP (Figure 3.2b, A), while 22% expressed the immature 
oligodendrocyte cell marker NG2 (Figure 3.2b, O), and 65% displayed the mature 
oligodendrocyte marker-O4. The expression of both neuronal and astrocyte cell markers 
simultaneously has been observed previously in vitro in hippocampal stem cells after treatment 
with bFGF in a serum-free medium [144], in the rat embryonic striatum at early stages of 
differentiation [145], and in immortalized embryonic mesencephalic mouse cells [146]. 
Similarly, postnatal forebrain neural progenitors can display mixed glial and neuronal properties 
in vitro when they co-express neuron-specific enolase (NSE), NF, and GFAP [147]. Thus, co-
expression of glial and neuronal cell markers seems to reflect multipotentiality at early stages of 




Figure 3.2: FNr-MDSCs display neurogenic and glial differentiation potential in vitro 
(a) FNr-MDSCs were able to generate neurospheres (three-dimensional non-adherent clusters of cells) in 
neurogenic medium within 7 to 10 days in culture (bright-field image). FNr-derived neurospheres express 
the neuronal cell markers β-tubulin III, NF, Neu-N, the myelin producing oligodendrocytes marker 
CNPase, and the astrocytic marker GFAP, and retained their nestin (a neuroepithelial progenitor marker) 
expression (inset). For all immunofluoresence staining, antibodies used are visualized in red with the 
nuclear stain (DAPI) seen in blue. (b) The FNr-derived neurospheres can be further differentiated into 
neurons (β-tubulin [red], N), oligodendrocytes (NG2 [green], O), and astrocytes (GFAP [green], A) 
(inset). The above results represent at least three independent experiments and negative controls were 
sections similarly processed but without primary antibodies (not shown). Scale bars represent 100 μm (a) 
or 50 μm in (b). 
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In addition, we found β-gal-positive (red) cells that expressed markers associated with 
Schwann cells, including the S-100 protein (green, Figure 3.3a), CNPase (green, Figure 3.3b), 
GFAP (green, Figure 3.3c), the neurotrophin receptor p75 (green, Figure 3.3d) and the tyrosine 
kinase receptor TrkA (green, Figure 3.3e). Taken together these results indicate that FNr-
MDSC-derived neurospheres can differentiate along all three neurogenic lineages, as well as into 




Figure 3.3: FNr-MDSCs can differentiate to Schwann cells in vitro 
FNr-derived neurospheres were differentiated further into cells that expressed markers found on Schwann 
cells (green), including: (a) the Schwann cell protein S-100, (b) CNPase, (c) GFAP, (d) the neurotrophin 
receptor p75 and (e) the tyrosine kinase receptor TrkA. All cells were positive for β-gal (red). Note: for 
negative controls, sections were similarly processed but without primary antibodies. They demonstrated 
negligible levels of non-specific background (data not shown). Scale bars represent 50 μm. 
3.2.2.2 FNr-MDSCs differentiate into Schwann cells and participate in the regeneration of 
the injured peripheral nerve 
To test the ability of FNr-MDSCs to participate in the regeneration of the peripheral 
nerve following injury, the cells were implanted into a critical-sized sciatic nerve defect in mice. 
To generate the nerve defect, the sciatic nerve was exposed and a 4- to 5-mm segment of the 
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nerve was removed (Figure 3.4a), resulting in a ~6.5- to 7-mm critical-size defect (a defect 
preventing autonomous healing) due to retraction of the nerve ends (n = 48; three independent 
experiments, Figure 3.4b). Equal volumes of either FNr-MDSCs or phosphate buffered saline 
(PBS) were implanted in the proximal and distal nerve stumps, and the wound was closed. 
Complete sciatic nerve regeneration was observed 5 to 9 weeks following transplantation in all 
of the mice that received FNr-MDSCs (n = 24; three independent experiments; Figure 3.4c), 
while the control group exhibited no regeneration, though some nerve sprouting on the proximal 
side was observed (n = 24; three independent experiments). Notably, blood vessel networks were 
also present around all regenerated nerve (Figure 3.4c, arrows). The regenerated nerve contained 
many donor nLacZ-positive cells (Figure 3.4d) and exhibited both NF (green) and CNPase (red) 
immunoreactivities (Figure 3.4e). Furthermore, the regenerated nerve contained nodes of 
Ranvier-like-structures, the gaps (about 1 micrometer in diameter) formed between myelin 





Figure 3.4: Transplanted FNr-MDSCs foster regrowth of critically-sized sciatic nerve defects 
(a) A 4- to 5-mm segment of the sciatic nerve was removed at the hind limb of each mouse, (b) resulting 
in a 6.5- to 7-mm defect. (c) Following transplantation of FNr-MDSCs into the critical-size defect, 
complete regeneration from proximal to distal end was observed. (d) Many nLacZ-positive cells (blue) 
were observed between weeks 5 and 9 following injury. “p” corresponds to the proximal stump, and “d” 
to the distal stump. (e) The regenerated nerve exhibited both NF (green) and CNPase (red) 
immunoreactivity. (f) CNPase (red) staining of the regenerated sciatic nerve revealed nodes of Ranvier-
like structures (white circles).  Scale bars represent 100 μm (d, e) or 10 μm (f).  
 
Cross sections of regenerated nerves exhibited many regenerated NF-positive axons 
(green) encompassing fluoromyelin-positive nuclei (red), indicating the presence of myelin-
producing Schwann cells forming myelin sheaths surrounding the regenerated axons (Figure 
3.5a). To confirm the differentiation of donor cells, we were able to detect ß-gal positive cells 
(red nucleated cells) expressing the glial and Schwann cell markers GFAP (green, Figure 3.5b, 





Figure 3.5: FNr-MDSCs differentiate toward Schwann cells in vivo 
(a) Cross-section of regenerated nerve showed nLacZ-positive cells (blue) located at the epineurium, and  
exhibited NF-positive axons (green, inset) surrounded by fluoromyelin-positive cells (red, inset). (b, c, d) 
Colocalization of ß-gal (red) with (b, c) GFAP (green) or (d) CNPase (green) and DAPI stain (blue) 
suggests possible differentiation of the FNr-MDSCs into Schwann cells (several double-positive cells 
denoted by arrows). Scale bars represent 100 μm (a) or 10 μm (b-d). 
 
Quantitative measurement of morphometric parameters, such as number of myelinated 
axons, myelin thickness, myelinated fiber area axonal cross-sectional area, and cross-sectional 
area of myelinated axons, and g-ratio (axon area : myelinated fiber area) [148] were compared 
between non-operated controls (uninjured) and FNr-MDSC-transplanted nerves on images taken 
with a transmission electron microscope (TEM) (Figure 3.6a-c). Ten weeks after implantation, 
the mid-section of the regenerated sciatic nerve contained an average number of 576 ± 33 
myelinated axons, compared to 387 ± 12 in uninjured nerves (P < 0.001). Cross-sectional area of 
myelianted axons and myelin thickness were assessed as a measure of regenerated fiber 
maturation. Myelinated axons in the FNr-MDSC group showed a median thickness area of 5.07 
μm2 as compared to 7.1 μm2 for the uninjured group (P < 0.001, Figure 3.6d) and cross-
sectional area of 8.53 μm2, versus 13.8 μm2 for the uninjured group (P < 0.001, Figure 3.6e). 
The median and 25th to 75th percentiles of g-ratio in mid-sections of the regenerated nerves were 
0.4 and 0.28 to 0.48%, respectively, versus the uninjured control group which was 0.5 and 0.42 
to 0.56%, respectively, (P < 0.001, Figure 3.6f). The increase in the number of myelinated axons 
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following FNr-MDSCs transplantation may be the result of axonal branching leading to an 
increased muscle tissue reinnervation and thus less axonal dieback [149]. Although the 
regenerated peripheral nerves are significantly different from the uninjured nerves for all 
morphometric parameters mentioned, we believe the high number of myelin-producing Schwann 
cells (arrows, Figure 3.6c) and the low g-ratio (Figure 3.6f) indicates thick myelination of the 
regenerated axons highlighting the process of myelination exhibited by the FNr-MDSC-




Figure 3.6: Regenerated nerve in FNr-MDSCs-treated mice show proper organization and 
remyelination  
(a-c) Electron microscopy of semi-thin cross-sections of (a) non-operated (uninjured) control, and (b, c) 
FNr-MDSC-regenerated peripheral nerve, shows a high number of myelin-producing Schwann cells 10 
weeks after implantation. Arrows indicate Schwann cells with surrounding myelinated axon. “Sc” 
corresponds to Schwann cells, “M” to myelin sheath, and “Ax” to axons, all of which are shown. (d-f) 
Graphical quantification of (d) myelin thickness, (e) area of myelinated axons, and (f) g-ratio (axon area: 
myelinated fiber area) represent the median values of both uninjured and FNr-MDSC-regenerated nerves 
to be significantly different (P < 0.001, Mann-Whitney Rank Sum Test). Sciatic nerve regeneration 
studies represent three independent experiments (n = 40 mice total). The morphometric parameters 
represent results from 5 mice (2 controls and 3 treated) and analysis of 1000 fibers. Scale bars represent 
10 μm (a-c). 
 
Functional recovery of regenerated sciatic nerves was determined by monitoring mice on 
a walking track. A detailed description of this method including the chosen parameters can be 
found in Appendix C. According to paw print analysis, FNr-MDSC-treated mice improved their 
walking pattern (Figure 3.7a). Further quantifications of paw prints revealed functional recovery 
determined by decrease in toe spread factor (Figure 3.7b), decrease in print length factor 
(Figure 3.7c), and increase in sciatic functional index (SFI) (Figure 3.7d), compared to PBS-
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treated control mice. The first signs of motor nerve recovery could be observed at 6 weeks post-
transplantation for the FNr-MDSCs (SFI: -52.4 ± 5.30) versus PBS-treated mice (SFI: -90 ± 
2.51, P < 0.001). After 10 weeks, the SFI significantly increased in the FNr-MDSC groups (-45.2 
± 14.2, P < 0.01), demonstrating further improvement in comparison with to the PBS-treated 
control groups (-86.1 ± 4.28). Furthermore, stem cell transplantation significantly decreased the 
toe spread factor (0.326 ± 0.058 versus 0.604 ± 2.51 for PBS-treated mice, P < 0.01), and print 
length factor (0.132 ± 0.05 versus 0.24 ± 0.036 for PBS-treated mice, P < 0.01) at 6 weeks post-
transplantation. These differences became even more evident at 10 weeks (toe spread 0.259 ± 
0.097 versus 0.558 ± 0.026, P < 0.01 and print length 0.117 ± 0.054 versus 0.209 ± 0.052, P < 
0.01). These results indicate that FNr-MDSCs facilitate functional nerve recovery possibly by 




Figure 3.7: Transplanted FNr-MDSCs assist in functional recovery of critically sized sciatic nerve 
defects 
(a) A depiction of representative paw prints from control- and FNr-MDSC-implanted mice at 6 and 10 
weeks post-implantation. (b-d) Paw print analyses, indicating that FNr-MDSC transplantation increases 
the ability of the mice to walk normally, quantified by (b) decrease in toe spread factor, (c) decrease in 
print length factor, and (d) an increase in SFI (sciatic functional index) compared to PBS-treated mice. * 
indicates a P < 0.05, and ** denotes a P < 0.001, Mann-Whitney Rank Sum Test. A total of 35 paw prints 
were analyzed/group/time point.  
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3.2.3 Microenvironment transformation: A murine model of human malignant Triton 
tumors 
3.2.3.1 FNr-MDSCs undergo transformation 11 weeks post-transplantation into a sciatic 
nerve defect  
Although complete nerve regeneration was observed 6 weeks post-implantation, we were 
surprised to find that ~70% (7/10) of the mice formed large neoplastic growths between weeks 
11 and 13 (Figure 3.8a,b). As these neoplasias were composed almost entirely of nLacZ-positive 
cells (data not shown), it was assumed that they originated from our donor cells. The neoplasias 
were highly invasive and positive for the myogenic cell markers α-smooth muscle actin (Figure 
3.5c, d) and desmin (Figure 3.8e, f). The tumors were also positive for the neurogenic marker 
NF (Figure 3.8g, h), and contained focal areas positive for S-100 (Figure 3.8i, j), areas that are 
double-positive for both NF and S-100 (Figure 3.8k, l) and pockets of unorganized myelin 
deposition, as seen by fluoromyelin staining (Figure 3.8m, n). According to histological 
features, the resulting tumors were classified as malignant peripheral nerve sheath tumors with 
rhabdomyoblastic differentiation, otherwise known as "Triton tumors" [150]. Notably, while 
tumorigenesis was observed, nerve regeneration was still apparent (white arrow indicating 
regenerated nerve, Figure 3.8n), implying that tissue regeneration and cellular transformation 






Figure 3.8: Between weeks 11 and 13, ~70% of mice implanted with FNr-MDSCs formed neoplastic 
growths 
(a, b) Hematoxylin and eosin staining of a tumor that formed in mice implanted with FNr-MDSCs. (c-l) 
The resulting tumors were classified as malignant peripheral nerve sheath tumors with rhabdomyoblastic 
differentiation (Triton tumors) by showing positivity for (c, d) smooth muscle actin (brown) and (e, f) 
desmin (brown), (g, h) NF (brown), and pockets of (i, j) S-100 (brown), (k, l) as well as cells positive for 
both NF (brown) and S-100 (purple). Some positive cells (brown in f, h, and j) or double-positive cells 
(cells with a brown nucleus and purple cytoplasm in k, and l) are indicated by arrows. (m, n) The 
neoplasias were also positive for fluoromyelin (green), showing areas of unorganized myelin deposition. 
(o) Image depicting fluoromyelin (red) and NF (green) double-stained sections from a regenerated nerve 
(white arrow) in the area of tumor. Total of 40 mice (3 independent experiments) were used to generate 
tumors; negative controls sections were similarly processed but without primary antibodies (not shown). 
Scale bars represent 100 μm. 
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3.2.3.2 Cells isolated from FNr-MDSC-derived tumors grow as neurosphere-like structures 
Cells were isolated from FNr-MDSC-derived tumors (TDCs) and cultured in regular 
proliferation medium (DMEM with 10% HS, 10% FBS, and 0.5% chick embryo extract). 
Although the cells were cultured in proliferation medium, they grew as neurosphere-like 
structures in the absence of neurogenic stimulation (Figure 3.9a) and were Lac-Z positive 
(Figure 3.9b). These spontaneously-occurring neurosphere-like structures were positive for ß-
tubulin III (Figure 3.9c), CNPase (Figure 3.9d), GFAP (Figure 3.9e), nestin (Figure 3.9f), and 




Figure 3.9: Cells isolated from FNr-MDSC-derived tumors (TDCs) maintain their neurogenic and 
myogenic differentiation potential in vitro 
(a) TDCs grew as neurosphere-like structures in the absence of neurogenic medium, and (b) were nLacZ-
positive (blue). (c-h) Immunofluorscent analysis of these spontaneously-occurring neurosphere-like 
structures demonstrated that they were positive for (c) β-tubulin III, (d) CNPase, (e) GFAP, (f) nestin, and 
(g) NF, but were negative for (h) Neu-N. For all immunofluoresence, the antibodies used are visualized in 
red, with the nuclear stain DAPI seen in blue. Scale bars represent 100 μm. 
 
Furthermore, TDCs had gained the ability to grow independently of anchorage (as 
determined by soft agar assays) while their parental counterparts (FNr-MDSCs) were incapable 




Figure 3.10: TDCs gained anchorage independent growth of colonies on soft agar  
(a) TDCs showed sign of colony formation when grown on soft agar, while (b) FNr-MDSCs were 
incapable of forming colonies. 
 
Cell cycle analysis of the parental FNr-MDSCs and TDCs revealed a shift of DNA 
content of the TDCs from the majority of cells being in the G0 phase (parental 45.6% vs. TDCs 
10.8%) to the G1/M phase (parental 34.6% vs. TDCs 66.7%), with more than 50% of the TDCs 
possessing more than a diploid amount of DNA (Figure 3.11a-d).  Cytogenetic analysis was 
conducted on both FNr-MDSC and TDC populations (Figure 3.11e, f). Analysis of the FNr-
MDSC culture revealed murine chromosomes with near-diploid and near-tetraploid chromosome 
constitutions; no clonal structural abnormalities were observed. However, analysis of the TDCs 
revealed chromosome numbers ranging from 46-118 indicating their abnormal karyotype. None 
of the TDCs had a chromosome complement that would be considered normal diploid or 
tetraploid. Two of the structural abnormalities observed in the TDCs appear to be clonal, since 
they were each observed in more than one cell.  Both of these were large, unidentifiable marker 
chromosomes, one of which appeared to be dicentric. Nonclonal chromosome abnormalities 
were seen in each of the TDCs. The karyotypic variability in these cells suggests the presence of 





Figure 3.11: Cell cycle and cytogenetic analyses confirm FNr-MDSCs to be normal while TDCs 
exhibit abnormalities  
(a-d) Cell cycle analysis of the parental FNr-MDSCs and TDCs was performed by FACS. Shown is the 
(a, b) DNA content and (c, d) graphical representation of the results, indicating the apoptotic, growth 0 
(G0), synthesis (S) and interphase/mitotic (G1/M) fractions. These results indicate that majority of TDCs 
are constantly in mitotic phase. (e, f) Cytogenic analysis of FNr-MDSCs and TDCs. (e) Depicted is a 
representative karyotype from the FNr-MDSC population (40,XX). (f) Karyotype of one of the cells from 
the TDCs. This cell has 68 chromosomes, is hypertriploid, and expresses several unidentifiable marker 
chromosomes, the largest of which appears to be dicentric. The karyotypic variability in TDCs suggests 
chromosomal instability. 
3.2.3.3 TDCs are serially transplantable, maintain their myogenic capacity in vitro, and 
tumorigenic in vivo   
To determine whether the TDCs were able to regenerate tumors, the cells were implanted 
into a critical-size sciatic nerve defect in mice. Following implantation, neoplastic growths were 
observed between weeks 4 and 8 in all implanted mice. Furthermore, these tumors were highly 
aggressive and invaded all of the surrounding tissue of the leg, destroying muscle as well as bone 
(arrows) (Figure 3.12a, b), and were composed of poorly undifferentiated rhabdomyoblasts 
(small blue and pink cells) (Figure 3.12a, b).  
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Though TDCs appear to be spontaneously neurogenic, they express the myogenic marker 
desmin (red, 12%) (Figure 3.12c) and retain their ability to form f-MyHC-positive myotubes in 
vitro (red, Figure 3.12d). While the parental FNr-MDSCs regenerated muscle fibers and showed 
no sign of tumorgenesis (n = 10 representing two independent experiments, Figure 3.12e), the 
TDCs rapidly formed tumors when injected into the skeletal muscle of mice. These tumors 
formed rapidly, 4 weeks post-implantation, in 100% (4/4 mice) of the mice and were composed 
of donor nLacZ-positive cells (n = 8 representing two independent experiments, Figure 3.12 f).  





Figure 3.12: TDCs are serially transplantable 
(a, b) Hematoxylin and eosin staining of a tumor generated from TDCs implanted into a sciatic nerve 
defect in mice, demonstrates the destruction of the bone, as seen by the pink, smooth stained portion 
(arrows). (c, d) In vitro myogenic analysis demonstrates that the TDCs possess expression of (c) the 
myogenic marker desmin (red, 12%) and have the ability to form myotubes in vitro, as seen by (d) f-
MyHC staining (red). (e, f) In vivo myogenic analysis demonstrates that although (e) parental FNr-
MDSCs showed myofiber regeneration after injection into the gastrocnemius muscles of mdx mice, and 
were detected up to 17 weeks without sign of tumor formation, the (f) TDCs implanted into the muscle 
formed tumor 100% of the time (10/10 mice), and as early as 4 weeks post-implantation. Note: the TDC 
reimplantation studies were performed in 2 separate experiments with a total of 16 mice; negative control 
sections were similarly processed without primary antibodies. They demonstrated negligible levels of 






Figure 3.13: Schematic of experimental design and results for Figure 3.12   
3.2.3.4 In vitro differentiation of FNr-MDSCs eliminates niche-specific transformation 
To rule out the possibility that our perceived transformation was due to the presence of 
pre-transformed cells within our FNr-MDSC population, and was, in fact, due to an imbalance of 
intrinsic and extrinsic signaling, we altered the intrinsic predilection of the cells by 
differentiating them prior to implantation. FNr-MDSCs were cultured as neurospheres for 14 
days, dissociated to a single cell suspension, and implanted into either the skeletal muscle of 
dystrophic mice or a critical-size sciatic nerve defect. If environmental cues were leading to the 
transformation of FNr-MDSCs, then altering the ability of cells to differentiate to a committed 
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lineage should abrogate transformation. When the dissociated neurospheres were injected into 
the skeletal muscle of mdx mice, poor muscle engraftment was observed (Figure 3.14a, b), as 
evident by a decrease in regeneration index (number of dystrophin positive myofibers per 
100,000 injected cells) compared to parental FNr-MDSCs (36.7 ± 9.45 versus parental FNr-
MDSCs 180.2 ± 49.1, P < 0.001, Figure 3.14 c). This suggests that in vitro differentiation of 
cells towards a neurogenic lineage reduced the ability of the cells to undergo myogenic 
differentiation. This was expected, since we postulated that differentiation of FNr-MDSCs prior 
to implantation would diminish their ability to respond to local environmental cues. More 
interestingly, when the dissociated FNr-MDSC-derived neurospheres were implanted into a 
critical-size nerve defect of mice, 80% (4/5 mice) of the mice formed fibrotic masses positive for 
Masson’s trichrome 4 weeks post-implantation (as seen by intense collagen deposits [blue] 
Figure 3.14d-e). The remaining (20%) mice exhibited no signs of tumor formation, nerve 
regeneration, or fibrosis. Furthermore, the implanted parental FNr-MDSCs generated large 
neoplastic growths that contained almost no trichrome-positive areas (5.63 ± 1.6 versus 
neurosphere-implanted group 32.5 ± 16.1, P < 0.001, Figure 3.14f). These findings are 





Figure 3.14: Neurogenic differentiation of FNr-MDSCs prior to implantation prevents 
transformation 
(a-c) Two weeks post-implantation FNr-MDSC-derived neurospheres showed a reduction in muscle 
regeneration when compared to the parental FNr-MDSCs. (a) The nLacZ donor-derived FNr-MDSC-
derived neurospheres (blue, n) could be detected in regenerated myofibers and (b) showed few 
regenerated dystrophin-positive myofibers (red) compared to undifferentiated FNr-MDSCs (not shown). 
(c) Graphical representation of the regeneration index (number of dystrophin positive fibers/100,000 
injected cells) of parental FNr-MDSCs and FNr-MDSC-derived neurospheres (NS). NS-injected mice 
yield a lower regeneration index compared to the undifferentiated FNr-MDSCs. (d-f) Dissociated (d) 
FNr-MDSC-derived neurospheres were implanted into a sciatic nerve defect, and tumor formation was 
abrogated. Furthermore, (e) 4/5 mice formed large fibrotic masses, as seen by hematoxylin and eosin 
staining with intense collagen deposits identified by Masson’s trichrome staining (blue, labeled c). (f) 
Graphical representation of the trichrome-positive area of parental FNr-MDSCs and NS. Parental FNr-
MDSCs show minimal signs of fibrosis (evident by a lower percentage of collagen-positive area). Scale 
bars represent 10 μm. Note: negative control sections were similarly processed without primary 







Figure 3.15: Combine scheme of experimental design and results for Figures 3.12 and 3.14  
3.3 DISCUSSION 
In this chapter, we have shown that a unique population of female neonatal MDSCs (FNr-
MDSCs) can be induced to express biochemical markers and morphological features consistent 
with differentiation toward myogenic and neurogenic phenotypes depending on the 
environmental cues that they received. In addition to their ability to undergo myogenesis, 
undifferentiated FNr-MDSCs express both neuronal and glial cell markers, can generate 
neurospheres, and can be further differentiated to all three neural cell lineages, as well as 
Schwann cells. The cells engrafted effectively into the gastrocnemius muscles of mdx 
(dystrophic) mice, and can be detected in regenerated myofibers 17 weeks post-implantation. 
FNr-MDSCs, when implanted into a critical-size sciatic nerve defect, functionally regenerated 
the nerve 5 weeks post-surgery. Furthermore, active differentiation of FNr-MDSCs into glial 
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cells, especially Schwann cells in vivo and the presence of LacZ+ donor cells suggest that these 
cells surround the regenerating axons, and promote direct axonal regeneration. We posit that this 
regeneration improves the probability of target organ innervation, thus facilitating functional 
recovery after transplantation. Although the number of donor-derived supportive cells was too 
small to conclude that regeneration was mediated only by donor cell differentiation, other 
mechanisms, such as recruitment of host cells at the site of injury, and release of cytokines that 
exert neuroprotective effects independent of neurogenesis [152-155] are likely to be also 
involved in nerve regeneration. Further evaluation is needed to determine the fate of grafted cells 
and clarify the mechanism of nerve regeneration.  
In addition to tremendous regenerative potential of MDSCs for both muscle and nerve, 
neoplastic growths classified as malignant Triton tumors (MTTs) were formed in ~70% (10/16) 
of mice between 11 and 13 weeks post-transplantation into sciatic nerve defect. MTTs, a type of 
malignant peripheral nerve sheath tumor (MPNST) with rhabdomyoblastic differentiation [156], 
comprise approximately 5 to 10% of all soft tissue sarcomas [150, 157] with crude two- and five-
year survival rates of 33 and 12%, respectively [158, 159]. Histopathologic and 
immunohistochemical results of our tumor samples demonstrated them to be positive for S-100, 
desmin and muscle-specific actin, similar to human MTTs [157, 160]. The cell cycle and 
chromosomal analyses demonstrate that the tumors generated from our FNr-MDSCs appear to be 
genetically unstable consistent with reported cases of MTTs in human [157, 160]. Hence, it 
appears that the tumors generated may be the murine equivalent of human MTTs that, to the best 
of our knowledge, have never been reported by previous investigators.  
The name triton was first used by Woodruff et al. [161] in reference to work done by 
Locatelli [162] supernumerary limbs containing bone and muscle were induced to grow on the 
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back of triton salamanders via the implantation of the sciatic nerve into the soft tissues of the 
back.  The traditional view to the origin of these tumors in humans suggest that either Schwann 
cells induce muscular differentiation of other cells, or malignant Schwann cells transform 
directly into skeletal muscle cells [156]. Recent studies on peripheral nervous system (PNS) 
tumors conclude that more differentiated cells, such as Schwann cells (or perhaps their closely 
related progenitors), rather than the stem cells may give rise to or facilitate the transformation 
[135, 163]. Our observed transformation could be explained by various hypotheses, one of which 
is of our particular interest. We introduce the idea that the stem/progenitor cells may become 
transformed when their intrinsic predilection (genotype) and extrinsic (environmental cues) 
signaling pathways become conflicted due to multiple differentiation signals. Our recent 
publication demonstrates how a lack of regulation of these signals is involved in the initiation of 
the oncogenic potential [164]. In this model, we have shown that progenitor cells isolated from 
the skeletal muscle of mice can undergo spontaneous microenvironment-specific transformation 
when expressing the osteogenic factor BMP4 [164]. The tumors generated were 
osteorhabdomyosarcomas, and formed only when a specific population of MDSCs was 
transduced with BMP4 and implanted into a myogenic environment [164]. Here we show 
another case of transformation that may attribute to concomitant signal-induced oncogenesis. 
Hence, if the progenitor cells used here receive both myogenic and neurogenic stimulation from 
the environment, as we suspect they do, this dual-signaling pathway may induces a state of 
continuous transient amplification. The fact that there is a time delay in our observed 
transformation may explain the time necessary for our murine cells to differentiate to the 
appropriate post-mitotic differentiated state to undergo transformation.  
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Cytogenetic analysis was carried out to exclude the possibility of culture-induced 
transformation. The cells used in this study possessed a normal karyotype, and did not show any 
signs of colony formation when grown in soft agar. They remained untransformed with no sign 
of tumorigenesis after subcutaneous implantation or intravenous injection over 1 year. We also 
did not observe any tumor formation when FNr-MDSCs were implanted into skeletal muscle of 
mdx mice for a period lasting over 17 weeks, or when differentiated towards a neurogenic 
lineage prior to injection. It is noteworthy that we have screened other cell populations isolated 
in our lab but didn’t find any other population to regenerate nerve. Our distinct cell population, 
FNr-MDSCs, has tremendous potential for nerve regeneration but also show susceptibility for 
transformation. High tendency of FNr-MDSCs towards Schwann cell (glial) differentiation may 
account for their receptiveness toward MTTs.  Recent report by Joseph et al. 2008 [163] shows 
that benign tumors and cancers of the PNS such as neurofibromatosis is caused by the loss of 
neurofibromin (Nf1) appeared to arise from differentiated glial and not neural crest stem cells 
and only in region of the PNS.   
To eliminate the possibility that the process of long term culturing or the nLacZ 
transduction may explain the underlying transformation phenomenon, we implanted early 
passage and control (non-transduced at later passage) parental cells and tumor formation was still 
observed in ~30% (2/6) and ~70% (4/6) respectively starting at 11-12 weeks post-
transplantation. The tumorigenesis and nerve regeneration observed here, though reproducible, 
were not mutually exclusive events. Mice that developed Triton tumors simultaneously displayed 
complete sciatic nerve repair and regeneration within the skeletal muscle. Our collected data 
present the possibility that our transformation may be related to the microenvironment. 
Microenvironment dictating the fate of adult stem cells is not a new concept and the finding that 
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stem cells may undergo spontaneous transformation is not unique to MDSCs. Stem cell and 
cancer biologists have known for many years that the microenvironment plays a role in 
maintaining and determining the fate of both normal and cancer stem cells. As mentioned by 
Kuica et al. [165], accumulating evidence start to recognize that if circulating normal stem cells 
or cancer stem cells exposed to a damaged environment may undergo malignant transformation 
over time. Mesenchymal stem cells (MSCs) have been shown to become tumorigenic [166-168] 
and have been implicated in childhood leukemia [169], epithelial cancers [170], and 
osteosarcomas [171-173]. Additionally, Leukemic stem cells express antigens similar to those 
expressed by hematopoietic stem cells (HSCs) [174]. The basis for observed transformations is 
not clear and origin of MTT remains unknown. Nevertheless, future experiments to explain the 
mechanism behind the origin of these rare tumors and the role of the stem/differentiated cells in 
that origin are required. 
In our effort to stop the FNr-MDSC transformation, we observed that differentiating the 
cells toward the neurogenic lineage prior to implantation abrogated tumorigenesis, but induced 
fibrotic-like tissue formation. The theory of halting the transformation of stem cells by 
differentiating them prior to implantation has been a long and established protocol for 
researchers using embryonic stem (ES) cells. In 2006, a publication demonstrated that co-
culturing human ES cells with immortalized human astrocytes from fetal midbrain tissue cells 
(making them more similar to adult progenitor cells prior to implantation), not only halt the 
transformation of the ES cells, but resulted in substantial and long-lasting restitution of motor 
function when transplanted into a Parkinsonian model [175]. We believe that the ability to 
immobilize transformation, at least in part, by removing the cells’ ability to respond to 
environmental cues (by differentiating our cells prior to implantation) is important. Potentially 
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by using a synthetic “nerve guide” [176], the FNr-MDSCs may be protected from non-neuronal 
environmental signals and “forced” to only undergo neurogenic differentiation, while avoiding 
an oncogenic phenotype. This may explain the reason for lack of reports on tumor formation in 
most studies performed by scientist using nerve guides for peripheral nerve regeneration [177]. 
Since the population of the MDSCs study here is a mixed population of many cells types 
including the myogenic and neurogenic cells, we can not disregard the possibility that under 
neurospheres conditions, myogenic cells are selected against. These cells may be the ones that 
underwent our perceived microenvironment-specific oncogenesis in vivo, and this may explain 
the lower regeneration index and lose of transformation potential by the FN-MDSC-derived 
neurospheres. If the myogenic cells are tumorigenic, then it may explain why the neural sphere 
cells lose their transformation potential and reduced muscle regeneration capacity in vivo.  
It should be emphasized that at this point the underlying mechanisms of our observed 
malignant transformation can not be fully explained; therefore, future studies are essential to find 
the responsible environmental cues. Also, the hypothesis of concomitant and conflicting 
differentiation signals inducing transformation mentioned here needs to be validated. We have 
isolated clones from the FNr-MDSCs and the titration studies on these clones are underway in 
order to determine their specific profiles individually. The results obtained here and future 
studies using our model display the potential to provide both a novel therapeutic approach to the 
treatment of peripheral neuropathies, and provides a potential paradigm shift in understanding of 
the cellular events responsible for the initiation events leading toward the development of 
MPNTs and MTTs. 
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3.4 CONCLUSIONS 
In conclusion, the data presented here demonstrate several key findings: female newborn muscle-
derived stem cells isolated via preplate technique (i) adopt neuronal and glial differentiation 
under controlled culture conditions, (ii) functionally regenerate peripheral nerve; (iii) undergo 
spontaneous transformation when implanted in vivo; and, (iv) this transformation may occur in 
an environment and time-dependent fashion; and, (v) differentiating the cells prior to 
implantation appears to eliminate transformation. Collectively, these findings provide evidence 
of myogenic and neurogenic differentiation potential of a unique population of MDSCs, and a 
useful murine model system to explore the relationship between effective tissue regeneration and 
microenvironment specific transformation.  
3.5 MATERIALS AND METHODS  
3.5.1 Cell isolation and culturing 
The Institutional Animal Care and Use Committee of Children’s Hospital of Pittsburgh approved 
all animal procedures. The MDSCs were isolated from the hind limbs of female neonatal mice 
(C57BL/6J; Jackson Laboratory) via the preplate technique previously described [122, 124]. 
Briefly, the muscle tissue was minced and processed through a series of enzymatic dissociations: 
0.2% of collagenase type XI (Sigma-Aldrich) at 37oC for 1 hr, 2.4 units/ml of dispase 
(Invitrogen) for 45 min, and 0.1% of trypsin-EDTA (Invitrogen) for 30 min. After enzymatic 
dissociation, the muscle cells were centrifuged and resuspended. The cells were then maintained 
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in proliferation medium (DMEM [Invitrogen] with 10% HS [Invitrogen], 10% FBS [Invitrogen], 
1% penicillin-streptomycin [Invitrogen] and 0.5% chick embryo extract [Accurate Chemical and 
Scientific Corporation]). Different populations of muscle-derived cells were isolated based on 
their adhesion characteristics. Small, round cells, appeared late in the preplate process (pp6) 
during isolation. These cells were allowed to adhere for approximately 2 weeks, at which point 
they began to proliferate to become long-term proliferating (LTP) cultures. LTP cultures were 
sub-plated at 100 cells/well in 12-well tissue culture plates to obtain MDSCs [122, 124]. The 
resulting MDSCs were then transduced with a retroviral vector encoding a LacZ reporter gene 
containing a nuclear localization sequence (nLacZ, kindly provided by Dr. Paul Robbins, 
University of Pittsburgh, Pittsburgh, PA) to enable donor cell tracking [178]. Limiting dilution 
was then used to sub-clone the transduced cells such that a population >90% nLacZ-positive was 
obtained. 
3.5.2 Flow cytometry analysis 
Fluorescence activated cell sorting (FACS) was used to analyze the expression of CD34, Sca-1, 
and CD45 (FACSAria cytometer using FACSDiva software; Becton Dickson). Cultured cells 
were trypsinized, centrifuged, washed with PBS containing 0.5% BSA (Sigma-Aldrich) and 
0.1% sodium azide (Sigma-Aldrich), and counted. The cell suspension was then divided into 
equal aliquots and centrifuged. The cells were placed on ice and resuspended in a 1:10 dilution 
of mouse serum (MS; Sigma-Aldrich) in PBS that was supplemented with 10% MS, and 
incubated for 10 min. Fluorescein isothiocyanate (FITC)- and Phycoerythrin (PE)-conjugated rat 
anti-mouse monoclonal antibodies (CD34, Sca-1, and CD45) were added to each tube for an 
additional 30 min. Separate cell portions received an equivalent amount of isotype control 
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antibodies. After several rinses, all fractions (including the controls) were labeled with 
strepavidin-allophcocyanin (APC) for 20 min. Just before analysis, 7-amino-actinomycinD (7-
AAD) was added to each tube for dead cell exclusion. All antibodies, as well as APC and 7-
AAD, were purchased from BD Bioscience Pharmingen. On average, 10,000 live single cell 
events were collected and analyzed. 
3.5.3 Myogenic Differentiation 
To induce differentiation, MDSCs were plated on collagen type-I-coated (Sigma-Aldrich) 24-
well plates in proliferation medium at a density of 1000 cells/cm2, and then shifted to 
differentiation medium (low serum: DMEM supplemented with 2% FBS and 1% penicillin-
streptomycin) 3 days after seeding. In vitro myogenic differentiation was evaluated after 5 days 
by immunocytochemical staining for f-MyHC, a marker of late myogenic differentiation, using 
the protocol described below.  
3.5.4 Neurosphere formation and differentiation 
To form neurospheres, FNr-MDSCs were plated as a suspension on 12-well plates at a 
concentration of 4x104 cells/ml in a medium consisting of Neurobasal™ A (Invitrogen), 100 
U/ml penicillin-streptomycin, L-glutamine (2 mM; Invitrogen), 1X B27 supplement (Invitrogen), 
bFGF (40 ng/ml; Invitrogen), and EGF (20 ng/ml; Sigma-Aldrich) using a similar protocol to 
that used by Romero-Ramos et al. [125]. Cells were maintained in this medium for 7 to 14 days, 
and the growth factors replaced every 3 to 4 days. The FNr-derived neurospheres were passaged 
before the diameter exceed 100 µm by enzymatic (using TrypLE [Gibco™]) and mechanical 
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(with P200 plastic micropipettor) dissociation, and supplemented with Neurobasal™ A, 1X B27, 
bFGF (20 ng/ml), and EGF (10 ng/ml). To induce differentiation, the FNr-derived neurospheres 
were collected, centrifuged, and gently triturated in a "differentiation medium" containing 10% 
FBS, and Neurobasal™ A supplemented with 1X B27 without the presence of mitogens. Single 
cell suspensions were plated on poly-D-lysine (Sigma-Aldrich, MW 70,000-150,000)-coated 8-
well CultureSlides (BD Falcon™) at an initial density of 5x104 cells/0.7 cm2. Plates were 
checked daily to determine the state of differentiation, and 50% of the medium was replaced with 
fresh differentiation medium when necessary (when the medium became acidic by turning 
yellow). Cells were incubated at 37°C in 5% CO2 in a fully humidified atmosphere for 7 to 14 
days and then fixed for immunocytochemical detection of neuronal/glial-specific antigens (see 
below).  
3.5.5 Immunocytochemistry  
The FNr-MDSCs (pre- and post-differentiation) were screened for several lineage-specific 
markers. Briefly, cells were fixed for 30 min in 4% paraformaldehyde (PFA; Fisher Scientific) in 
PBS (pH 7.4; Invitrogen), washed, and incubated for 10 min at room temperature with PBS plus 
0.3% Triton X-100 to permeabilize the cell membrane. They were incubated with 10% normal 
donkey serum (DS; Jackson ImmunoResearch Laboratories) or goat serum (GS; Vector), to 
block non-specific binding, for 60 min. Cells were incubated at 4°C overnight with the following 
primary antibodies (in 2.5% DS or GS): goat anti-Nestin (1:1000; Santa Cruz Biotechnology 
Inc.), mouse anti-β-tubulin III (TU-20, 1:500; Chemicon), mouse anti-CNPase (1:200; Sigma-
Aldrich), rabbit anti-S-100 (1:500; Sigma-Aldrich), goat anti-NGFR p75 (c-20, 1:200; Santa 
Cruz Biotechnology Inc.), rabbit anti-TrkA (763, 1:500; Santa Cruz Biotechnology Inc.), rabbit 
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anti-GFAP (1:500; Chemicon), rabbit anti-NF (neurofilament 150 kD, 1:500; Chemicon), mouse 
anti-Neu-N (neuronal nuclei, 1:100; Chemicon), mouse anti-O4 (1:200; Chemicon), rabbit anti-
NG2 (1:200; Chemicon). The secondary antibodies to the appropriate species used were as 
follows: donkey anti-mouse IgG-AlexaFluor® 594- or 488-conjugated (1:500; Molecular 
Probes), donkey anti-rabbit IgG-AlexaFluor® 594- or 488-conjugated (1:500; Molecular Probes) 
for 30 min, and Cy3-conjugated anti-goat IgG (1:1000; Sigma-Aldrich) against nestin antibody 
for 60 min. For desmin and f-MyHC immunocytochemical staining, the cells were fixed with 
cold methanol for 2 min and blocked with 10% HS (Vector) for 1 hour and incubated with the 
primary antibody (1:200, mouse; Sigma-Aldrich) in 2.5% HS at 4°C overnight. After thorough 
washing, the cultures were incubated at room temperature for 45 min with the secondary 
antibody biotinylated anti-mouse IgG (1:250; Vector) and subsequently reacted with 
streptavidin-conjugated Cy3 (1:500; Sigma-Aldrich) at room temperature for 20 min. To 
visualize the nuclei, the cultures were then incubated with DAPI (4′, 6′ diamidino-2-
phyenylindole, 100 ng/ml; Sigma-Aldrich) for 10 minutes. Culture slides (BD Falcon™) were 
mounted with Vectashield® medium (Vector). Bright-field and fluorescent images were taken 
using a Nikon Eclipse E800 microscope equipped with a Spot digital camera and software 
system (v. 3.0.4; Diagnostic Instruments) or a Leica DMIRB microscope equipped with a Retiga 
1300 digital camera (Q imaging) and Northern Eclipse software system (v. 6.0; Empix Imaging, 
Inc.). Cells were systematically quantified in at least 15 fields across the slides, or wells of 
culture dishes from four to six independent experiments. Controls included omitting the primary 
or secondary antibodies during the procedure. 
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3.5.6 Neurosphere and stem cell transplantation 
To examine myogenic differentiation, 2x105 viable FNr-MDSCs or single cell suspension from 
FNr-derived neurospheres (14 days in culture) were suspended in 20 μL of PBS and injected into 
the gastrocnemius muscle of 6- to 8-week-old mdx mice (C57BL/10ScSn DMDmdx/J; Jackson 
Laboratories) via an Ultra-Fine II syringe (BD BioSciences). At 2 and 17 weeks post-
transplantation, mice were sacrificed and the gastrocnemius muscles were harvested and flash 
frozen in liquid nitrogen-cooled 2-methybutane. Serial cryosections 10 μm in thickness were 
prepared from frozen muscles for immunohistochemical analysis. Muscle regeneration was 
quantified by manually counting the number of dystrophin-positive myofibers in an area 
containing the largest graft and calculating the regeneration index. Neurogenic differentiation 
was examined by creating a 7-mm sciatic nerve defect in 6- to 8-week-old SCID mice. 
Immediately thereafter, a viable single cell suspension of 3x105 FNr-MDSCs, FNr-derived 
neurospheres, or an equal volume of PBS (15 μL), was injected into proximal and distal nerve 
stumps. Some of the mice from each group were sacrificed 6 weeks after transplantation, and the 
hind limbs, including the sciatic nerve, were harvested, frozen, and cryosectioned for further 
analysis. The rest of the mice were maintained until later time-points (up to 15 weeks) to check 
for possible tumor formation.  
3.5.7 Histochemistry 
Sections were fixed in 1% glutaraldehyde (Sigma-Aldrich), and stained for nLacZ expression 
(using X-Gal solution 3 hours at 37°C) for donor cell tracking, and then counterstained with 
eosin [179]. Masson’s modified protocol was used to determine the amount of collagen content 
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in the fibrotic tissue using Masson’s trichrome staining. Slides were processed and stained as 
detailed in the manufacturer's protocol (Masson’s trichrome stain kit, K7228; IMEB Inc.), which 
stains collagen blue, muscle fibers red, and nuclei black. 
3.5.8 Immunohistochemistry  
To colocalize the donor cells with neurogenic and/or glial cell markers, the tissue sections were 
incubated with mouse anti-ß-galactosidase (1:200; Chemicon) and rabbit anti-GFAP (1:1000; 
Chemicon) overnight at 4°C. Sections were rinsed with PBS and incubated with Cy3-conjugated 
anti-rabbit IgG (1:250; Sigma-Aldrich) for 30 min. To detect the donor cells, biotinylated anti-
mouse IgG (1:200; Vector) was added to the slides for 90 min, and subsequently reacted with 
streptavidin-conjugated FITC (1:500; Sigma-Aldrich) at room temperature for 20 min. Muscle 
sections: Cryosections were fixed with 5% formalin (Sigma-Aldrich) and blocked with 10% HS 
in PBS for 1 hour at room temperature or 4ºC overnight, and then incubated with rabbit anti-
dystrophin (1:300; Abcam). The sections were washed in PBS and incubated with Cy3- 
conjugated anti-rabbit IgG (1:500; Sigma-Aldrich) in PBS for 30 min. For desmin staining, fixed 
sections were incubated with mouse anti-desmin (1:200; Sigma-Aldrich); the following steps 
were performed in accordance with the MOM kit (FMK-220; Vector) manufacturer's 
instructions, except that streptavidin-conjugated Cy3 was used to replace fluorescence-
conjugated avidin. Nuclei were revealed by DAPI. Sciatic nerve sections: Cryosections of the 
hind limb were first immunostained for FluoroMyelin red (Molecular Probes) according to the 
protocol provided by the manufacturer, and then fixed in 4% PFA blocked with 5% DS for 1 
hour, and incubated with rabbit anti-NF (1:300, Chemicon) for 2 hours at room temperature. The 
tissues were then rinsed with PBS and stained with donkey anti-mouse IgG-AlexaFluor® 488-
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conjugated for 20 min. In addition, the regenerated sciatic nerves were cryo-sectioned 
longitudinally, fixed with 5% formalin, blocked with 10% HS, and incubated overnight at 4°C 
with both rabbit anti-NF (1:300; Chemicon) and mouse anti-CNPase (1:200; Sigma-Aldrich) 
antibodies. The next day, the sections were rinsed with PBS and incubated with biotinylated anti-
mouse IgG (1:200; Vector) for 1 hour, and subsequently stained with streptavidin-conjugated 
Cy3 (1:500; for CNPase immunostaining) at room temperature for 20 min. Sections were then 
exposed to donkey anti-rabbit IgG-AlexaFluor® 488-conjugated (1:500; Molecular Probes) for 
30 min to immunostain for NF-positive axons. Controls included omitting the primary or the 
secondary antibodies during the procedure. Tumor sections: Slides were processed and stained 
as detailed in the manufacturer's protocol (Vectastain® Elite ABC kit; Vector Laboratories) with 
anti-mouse or rabbit IgG appropriate to primary antibody including: rabbit anti-NF (1:500; 
Chemicon), rabbit anti-S-100 (1:500; Sigma-Aldrich), and mouse anti-desmin (1:200; Sigma-
Aldrich). Slides were developed using the peroxidase 3,3′-diaminobenzidine (DAB) substrate kit 
(Vector Laboratories). For the purpose of double labeling, a sequential staining of each primary 
antibody was performed using anti-rabbit IgG Vectastain ABC kit (Vector Laboratories). The 
slides were developed using DAB Substrate Kit (brown) for NF and Vector VIP Substrate Kit 
(purple) for S-100 (both from Vector Laboratories).  
3.5.9 Morphometric analysis of the regenerated nerve 
Some of the regenerated nerves 10 weeks post-operation were fixed in 2.5% glutaraldehyde (EM 
grade, Taab Chemical) in 0.1M phosphate buffer (pH 7.3; Fisher Scientific) overnight at 4°C for 
light and transmission electron microscopy studies. The contralateral sciatic nerve harvested at 
the same level served as a “normal” control. The nerves were then rinsed in PBS, post-fixed in 
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1% osmium tetroxide (Electron Microscopy Sciences) with 0.1% potassium ferricyanide (Fisher 
Scientific), dehydrated in a series of ethanol solutions (30% - 90%; Fisher, and 100% [Ethanol 
200 Proof]; Pharmco), exposed to propylene oxide twice for 10 min each and embedded in Epon 
(Dodecenyl Succinic Anhydride, Nadic Methyl Anhydride, Scipoxy 812 Resin and 
Dimethylaminomethyl; Energy Beam Sciences). All grafted segments were carefully oriented in 
order to obtain sections perpendicular to their long axis. Semi-thin (300 nm) sections were cut 
using a Lecia Ultracut and stained with 0.5% toluidine blue (Fisher Scientific) and examined 
under light microscope (Olympus BX51) with Magnafire 2.1A image capture software, and 
quantified for the number of the myelinated axons. Ultrathin sections (65 nm) at distal, mid, and 
proximal ends were obtained using a Leica Ultracut Microtome (Leica) and stained with 2% 
uranyl acetate (Electron Microscopy Sciences) and Reynold’s lead citrate (Fisher Scientific), and 
examined on a JEOL JEM-1011 transmission electron microscope in collaboration with Dr. 
Simon Watkins (University of Pittsburgh, Pittsburgh, PA).  The number of myelinated axons in 
~10,000 μm2 of the cross-sectional area of the nerve was counted, and median area of myelin 
thickness, median cross-sectional area of myelinated axons, and g-ratio (axon area/myelinated 
fiber area) were examined in mid-sections of the regenerated nerves. Each section was divided 
into four quarters. Each quarter of the nerve was analyzed individually, and morphometric 
parameters of 300-500 fibers were calculated using the Northern Eclipse software system (v. 6.0; 
Empix Imaging, Inc.) following image capture, background subtraction, image enhancement, 
automatic thresholding, and final editing. 
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3.5.10 Functional assessment 
Functional recovery was analyzed using a walking track assessment, and quantified by 
measuring two factors including toe spread (TS, distance from the first to the fifth toe), paw 
length (PL, distance from the third to the heel) taken from the mouse footprints of uninjured 
(normal) and experimental sides. Paw prints were collected on white paper with the hind paws 
painted with black ink and evaluated based on published model for recovery of sciatic nerve 
motor function [180, 181]. Footprint parameters were scanned and analyzed with imaging 
Northern Eclipsed Software system. The sciatic functional index (SFI) was calculated using 
previously described protocol [180, 181] at 6 and 10 weeks after injury. A more detailed 
description of the model, schematics, and calculations including the formulas can be found in 
Appendix C. 
3.5.11 Soft agar analysis 
Cells were suspended in DMEM over a 0.6% agar (Sigma) underlay at concentrations of 100, 
500, and 1000 cells/well. The cultures were allowed to grow for 2 weeks and then scored for 
colonies as a % (number of colonies/100 cells). 
3.5.12 Cytogenetic analysis 
Cytogenetic analysis was carried out by the University of Pittsburgh Cancer Institute 
Cytogenetics Facility. The cells from both the FNr-MDSC (passage 36) and TDC (passage 12) 
populations were harvested following mitotic arrest with a 2 h treatment with ColcemidTM 
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(0.1µg/ml, Irvine Scientific). The cells were then incubated in hypotonic KCl (0.075M) for 30 
min at 37oC, and fixed in 3:1 methanol: glacial acetic acid for 20 minutes, followed by two 
washes in fixative. Slides were prepared from the cell suspensions and aged overnight at 60°C. 
Chromosomes were trypsin-Giemsa banded and 20 cells were counted and analyzed from each 
cell culture.  
3.5.13 Statistical analysis 
Statistical analysis was carried out using SigmaStat (Jandel Scientific v2.0) software package. 
Morphometric parameters are expressed as the median values, 25th-75th percentiles. Direct 
comparisons between treatment and control groups for myelianted fiber counts data was 
analyzed using Student’s t-test. However, the data for the myelin thickness, myelinated fibers 
area, axon area, and g ratio violated the assumptions of normality and variance and these were 
compared using Mann-Whitney Rank Sum test. The Student’s t-test or the Mann-Whitney Rank 






4.0  HUMAN MUSCLE-DERIVED PROGNITOR CELLS: POTENTIAL FOR CELL-
MEDIATED THERAY FOR PERIPHERAL NERVE INJURY 
4.1 INTRODUCTION 
The identification of cell populations capable of neural differentiation has generated great 
interest [182, 183] due to limited capacity of neural tissue for intrinsic repair and regeneration. 
Stem cells from embryonic tissue are able to expand and differentiate into multiple lineages 
including neural lineage in vitro and in vivo. However, there are still some limitations on the 
practical use of embryonic stem cells because of ethical questions [184, 185].  
Until recently, myogenic cells have primarily been used for muscle fiber regeneration 
[124, 186, 187]. These cells are normally mitotically quiescent but become activated and start to 
divide in response to injury [188]. However, studies in the past few years have shown that adult 
skeletal muscle tissue contains progenitor cells able to differentiate into several phenotypes of 
mesodermal and ectodermal origin such as astrocytes and neurons [125, 189-191]. This suggest 
that reservoirs of stem cells may reside in skeletal muscle that can retain the potential to 
transdifferentiate from one phenotype to another, presenting exciting possibilities for cellular 
therapies.  In fact, studies have reported using these cells for experimental treatment of a variety 
of diseases and disorders, including clinical trials for urological dysfunction [192] and cardiac 
repair [193-200].  The rationale behind using skeletal-derived cells (myoblasts, satellite cells, 
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and skeletal muscle-derived stem cells [MDSCs]) is that it can be easily isolated from a simple 
muscle biopsy of adult tissue in a relatively noninvasive method, readily be expanded in vitro, 
and transplanted in an autologous manner.  This approach can also eliminate the ethical issues 
raised by using of embryonic or fetal tissues as a source.  
Though recently, it has been demonstrated that adult human skeletal muscle includes 
progenitor cells that can generate cells with neurogenic properties in vitro [125, 201, 202], their 
engraftment potential in vivo needs further investigation. Obtaining encouraging results in our 
sciatic nerve regeneration model using mMDSCs, led us to utilize the same isolation technique 
[124, 142] to isolate MDSCs-like cells from human muscle biopsies. We sought to determine if a 
fraction of slowly adhering cells (SACs) containing human muscle-derived progenitor cells 
(hMDPCs) could (i) adopt neuronal/glial phenotype in culture; (ii) help to restore severed sciatic 
nerve defect; (iii) survive and engraft in the sciatic nerve defect area post-implantation; and, (iv) 
acquire Schwann cell-specific phenotype after transplantation. We hypothesized that hMDPCs 
can adopt neuronal and glial phenotypes under controlled culture conditions, and transplantation 
of hMDPCs improves the regeneration and functional recovery of critically sized sciatic nerve 
defects in mice following injury. 
hMDPCs were screened for a series of neurogenic and glial cell markers pre- and post-
differentiation using immunocytochemistry and real time PCR (RT-PCR). The efficacy of sciatic 
nerve regeneration and remyelination were evaluated quantitatively by immunohistochemistry 
and electron microscopy. Recovery of motor function was assessed by monitoring mice on a 




4.2.1 hMDPCs differentiate into phenotypically mature neuronal and glial under 
controlled culture conditions 
hMDPCs generate neurospheres, starting as early as after 2 days in neurogenic culture medium 
(Figure 4.1a) that are successfully passaged and expanded. hMDPCs-derived neurospheres 
express the astrocyte marker, GFAP (Figure 4.1b) and the neuron marker, β-tubulin III (Figure 
4.1c). Neurospheres also contain cells co-expressing β-tubulin (red) and Schwann cell protein, S-
100 (green) (Figure 4.1d, arrow), while others only express β-tubulin (Figure 4.1d, arrowhead). 
The hMDPCs-derived neurospheres can be further differentiated into glial and Schwann cells 
positive for p75 (Figure 4.1e) and GFAP (Figure 4.1f) and mature neurons positive for β-
tubulin (Figure 4.1g) and MAP2ab (Microtubule associated protein 2ab, Figure 4.1h). Nuclei 







Figure 4.1: Differentiated hMDPCs under controlled culture conditions express mature phenotype 
of neuronal and glial lineage including Schwann cells 
(a) hMDPCs are able to generate neurospheres. These hMDPCs-derived neurospheres expressed the (b) 
astrocytic and Schwann cell marker, GFAP, (c) the mature neuronal marker, β-tubulin III. (d) Single 
suspended neurospheres exhibited co-expression (yellow, arrow) of both markers β-tubulin III (red) and 
S-100 (green) while some cells only showed β-tubulin III expression (red, arrowhead). The hMDPCs-
derived neurospheres can be further differentiated into glial and Schwann cells positive for (e) p75 and (f) 
GFAP and mature neurons positive for (g) β-tubulin and (h) MAP2ab (the nuclear stain DAPI, seen in 
blue and human lamin A/C seen in green). (i) Above data represent three to six independent experiments. 
Scale bar in (a) applies to all other panels except for (d). Scale bars represent 100 μm. 
4.2.2  Differentiated hMDPCs show upregulation in both neuronal and glial cell marker 
expression when compared to undifferentiated counterparts.  
Three distinct undifferentiated (UN) cell populations of hMDPCs underwent neurosphere (NS) 
formation and terminal differentiation (TD).  Real-time PCR analysis was carried out to further 
analyze the expression level of several neuronal and glial cell markers prior and post-
differentiation. Differentiation of hMDPCs toward neurospheres increased the expression of 
neuroectodermal marker, Pax6 (4-fold), a gene expressed in neural stem cells and in 
neurospheres [203] when compared to undifferentiated counterpart (Figure 4.2). The expression 
of mature neuronal marker MAP2ab increased (2-fold) after terminal differentiation when 
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compared to undifferentiated hMDPCs. In particular, differentiation of hMDPCs highly up-
regulate the expression of the Schwann cell marker, S-100 (10-fold NS; 3-fold TD) and the 
astroglial and Schwann cell marker, GFAP (20-fold NS; 10-fold TD) at neurospheres and  
terminal stages of differentiation respectively, compared to undifferentiated controls (Figure 
4.2). Furthermore, terminal differentiation of hMDPCs revealed 25-fold increase in the 
expression of oligodendrocytes marker, OSP. These results further confirm hMDPCs potential to 
differentiate into myelin producing glial cells.  
 
 
Figure 4.2: The expression level of all markers up-regulated after differentiation of hMDPCs when 
compared to initial undifferentiated hMDPCs.    
Quantitative transcription profile of neurospheres (NS), terminal differentiation (TD) into glial and 
neuronal cell types compared to undifferentiated (UN) hMDPCs counterparts. Data are pooled from three 
independent experiments obtained from hMDPCs isolated from three distinct skeletal muscle biopsies. 
Expression levels are expressed relative to the housekeeping gene Cyclophlin.   
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4.2.3 hMDPCs promote functional regeneration of severe sciatic nerve defects after 
injury 
hMDPCs from four separate isolations were transplanted into critical-size sciatic nerve defects in 
SCID mice (n = 96 mice; three independent experiments). Complete regeneration from proximal 
(p) to distal (d) stump was observed as early as 6 weeks after injury (Figure 4.3a), whereas 
nerve gaps in which PBS was injected (n = 20 mice) exhibited minimal regeneration (Gap, 




Figure 4.3: hMDPCs regenerate severe sciatic nerve defect 
(a) Following transplantation of hMDPCs into critical-size (7-mm) sciatic nerve defects of SCID mice, 
complete regeneration from proximal (p) to distal (d) stump was observed as early as 6 weeks after injury. 
(b) The nerve gap injected with PBS exhibit minimal regeneration (Gap). 
 
Cross-sections of regenerated nerves exhibited NF-positive axons (green) enclosed by 
fluoromyelin-positive cells (data not shown). Longitudinal sections of regenerated nerves 
exhibited both NF (green) and CNPase (red) immunoreactivity (Figure 4.4a). CNPase (red) 
staining of the regenerated sciatic nerve revealed node of Ranvier-like structures (white circles) 
similar to FNr-MDSCs regenerated nerves (Figure 4.4b). Regenerated nerves positive for 
Schwann cell marker GFAP (green) contained many donor PCNA positive cells (red) that 
particularly situated themselves in front and along the growth cones of the nerves (Figure 4.4c). 
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Detecting PCNA+ donor cells (red) positive for GFAP (green) and CNPase (data not shown) 
suggests differentiation of hMDPCs into glial cells particularly Schwann cells (Figure 4.4d, e; 




Figure 4.4: hMDPCs undergo glial differentiation particularly Schwann cells in vivo  
(a) Longitudinal sections of the regenerated nerve exhibited both NF (green) and CNPase (red) 
immunoreactivity. (b) CNPase (red) staining of regenerated sciatic nerve revealed nodes of Ranvier-like 
structures (white circled) at higher magnification. (c) Close association and distribution of human donor 
cells positive for proliferating nuclear antigen specific, PCNA (red), were observed with growing cone of 
regenerated sciatic nerve stained with GFAP (green). (d, e) Colocalization of PCNA positive donor cells 
(red) with GFAP (green) and DAPI stain (blue) suggests possible differentiation of the hMDPCs into glial 
cells  (several double-positive cells denoted by arrows). Scale bars represent 100 μm (a, d, and d) or 10 
μm (b, e). 
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Ten weeks post-transplantation, regenerated nerves contain many nerve fibers with 
organized fascicles (F) surrounded with perineurium (P, arrows) (Figure 4.5a). The mid-sections 
of the regenerated sciatic nerves contained an average 450 ± 21 myelinated axons, compared to 
356 ± 17 in non-operated (uninjured) control nerves, this differences was statistically significant  
(P = 0.002, ANOVA). Pairwise Multiple Comparison showed a significant difference (P < 0.05, 
Tukey Test) between uninjured control and hMDPCs-treated nerves, while no significant 
difference was observed among the hMDPCs isolated from different donors. Electron 
microscopy at proximal and mid-sections of regenerated nerves revealed proper regeneration, 
absence of connective tissue fibrosis, and many myelinated Schwann cells (arrows, Figure 4.5b 
and c respectively). The myelinated axons in the hMDPCs group showed a median cross-
sectional area of 8.6 μm2, versus 15.5 μm2 for uninjured control nerves (P < 0.001, Figure 4.5d), 
and median myelin thickness of 5.2 μm2 versus 8.1 μm2 (P < 0.001, Figure 4.5e. The median 
and 25th to 75th percentiles of g-ratio in mid-sections of the regenerated nerves were 0.48 and 
0.41 to 0.54%, respectively, as compared to 0.49 and 0.4 to 0.56% for uninjured control group 
(Figure 4.5f), indicating a close resemblance between the regenerated nerves by means of 




Figure 4.5: Regenerated nerves in hMDPCs-treated mice show proper organization and 
remyelination  
(a) Eight to ten weeks post-transplantation, light microscopy image of regenerate nerve stain with 
toluidine blue show organized nerve regeneration with perineurium (P, arrows) surrounding the nerve 
fascicles (F). (b, c) Electron microscopy at proximal and mid-sections of the regenerated nerves revealed 
proper regeneration, absence of connective tissue fibrosis, and many myelinated Schwann cells in 
proximal and mid-sections (arrows, b and c respectively). “Sc” corresponds to Schwann cells, “M” to 
myelin sheath, and “Ax” to axon. (d-f) Graphical quantification of the morphometric parameters display 
the median values for (d) area of the myelinated fiber, (e) myelin thickness, and (f) g-ratio (axon area : 
myelinated fiber area) of the regenerated nerve to the non-operated (uninjured) control nerves. A total of 
35 mice were transplanted. The morphometric parameters represent results from 5 mice (2 controls and 3 
treated) and analysis of at least 600 fibers/group. Scale bars represent 10 μm. 
 
Paw print analyses revealed an enhanced gait recovery of hMDPCs-treated mice in 
comparison with PBS-treated mice (Figure 4.6). This improvement is quantitatively supported 
by significant decrease in both toe spread factor (Figure 4.7a) and print length factor (Figure 
4.7b), and significant increase in SFI (Figure 4.7c) for hMDPCs-treated versus PBS-treated 
mice in each consecutive weeks after injury. These differences started at week two and became 
highly evident at week fourteen (toe spread: 0.18 ± 0.091 versus 0.514 ± 0.021, P < 0.01, print 
length: 0.161 ± 0.037 versus 0.338 ± 0.052, P < 0.01, and SFI: -37.2 ± 1.17 versus -86.1 ± 2.55, 
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P < 0.001). It is noteworthy that both hMDPCs isolated from different donors showed close 




Figure 4.6: Representation of paw prints from PBS and hMDPCs-treated mice 
A depiction of representative paw prints from PBS (control) and hMDPCs-treated mice are shown for 14 
consecutive weeks post-implantation. Paw print analyses indicate that transplantation of hMDPCs 
isolated from two different patient (hMDPCs 1 and 2) increases the ability of the mice to walk normally 




Figure 4.7: hMDPCs improve functional recovery after injury 
(a-c) Further quantification of data obtained by measuring the paw print factors revealed functional 
recovery determined by (a) a significant decrease in both toe spread factor and (b) print length 
factor, and (c) significant increase in SFI for hMDPCs-treated versus PBS-treated mice in each 
consecutive weeks after injury. (*P < 0.05 indicates PBS vs. hMDPCs isolated from patient 1, 
ANOVA, Kruskal-Wallis on Ranks;  § P < 0.05 indicates PBS vs. hMDPCs isolated from patient 2, 
ANOVA, Kruskal-Wallis on Ranks). Data present three independent experiments. A total of 30-90 paw 
prints were analyzed/group/time point.  
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4.3 DISCUSSION 
Skeletal muscle is not commonly used as a source of neurogenic cells. However, adult human 
skeletal muscle was recently shown to include progenitor cells with neurogenic properties in 
vitro [201, 202], but regeneration capacity of these cells has not been demonstrated yet. Our 
findings suggest that progenitor cells isolated from the skeletal muscle of humans via modified 
preplate technique express neuronal and glial cell markers and undergo myogenic and 
neurogenic differentiation in vitro. These cells formed neurospheres and further differentiated to 
all neuronal and glial cell lineages including the most important cells involved in peripheral 
nerve, the Schwann cells. These findings reinforce that skeletal muscle contains a 
progenitor/stem cell population with a high capacity for neurogenesis. Furthermore, these cells 
survived and grafted in the area of sciatic nerve defect post-transplantation and greatly enhanced 
the restoration of critically sized sciatic nerve defect with induction of nerve fiber regeneration 
through myelin-producing Schwann cell-like cells. We posit that regeneration of motor axons in 
cell transplanted animals improved the probability of muscle tissue reinnervation resulting to a 
functional recovery. Together these data provide evidence, at both the anatomical and functional 
levels, that implantation of hMDPCs are capable of significantly accelerating the regeneration of 
peripheral nerve damage.   
It is important to mention that transplantation of hMDPCs in our sciatic nerve model of 
mice did not lead to development of abnormal growth. While nerve regeneration and functional 
recovery was observed, no sign of tumorigenesis was detected up to one year following 
implantation. From a theoretical perspective, hMDPCs perhaps more differentiated/committed 
cells compared to undifferentiated murine MDSCs counterparts. As previously stated, 
differentiated cells seems to be less prone to microenvironment related transformations. Also, 
 73 
due to some differences in mouse and human growth factors and their receptors, hMDPCs may 
show a lower specific activity to the corresponding mouse cytokines. This makes hMDPCs less 
influenced by exogenous murine growth factors and their environmental cues and lowers the 
chance of transformation. These possibilities remain to be confirmed.   
Although a limited number of donor cells underwent Schwann cell differentiation, other 
mechanisms are most likely responsible for our observe nerve regeneration. These mechanisms 
may include recruitment of host Schwann cells at injury site, production and/or release of growth 
factors by the donor/host cells. These growth factors play an important role in survival, 
recruitment, and differentiation of the host/donor cells toward supporting cells, the Schwann 
cells, to enhance continuity of the axonal regeneration at the site of injury. Previous studies have 
proposed the expression of certain growth factors by implanted cells as a possible mechanism for 
functional improvement [196, 197, 204]. In addition, differentiation of host cells toward 
Schwann cell may be activated by transplantation of the donor cells stimulating the body to heal 
itself more effective manner. Further evaluation is needed to determine the fate of grafted cells, 
and clarify the mechanism behind our observed regeneration.  
4.4 CONCLUSIONS 
Here we report that cells isolated from adult human skeletal muscle using a modified preplate 
technique can form neurospheres and be further differentiated into all three main cell lineages of 
central nervous system, neurons, oligodendrocytes and astrocytes, as well as peripheral nerve 
supporting cells, the Schwann cells. Following transplantation of these cells into a peripheral 
nerve injury model, complete functional regeneration was observed after injury.  In addition, 
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regeneration improved the ability of mice to walk normally. These results help to further validate 
the multipotentcy of progenitor cells isolated from human skeletal muscle via modified preplate 
technique and facilitate their usage as a valuable source for cell-mediated therapies. 
In addition, this work represents one of the first attempts to have used isolated muscle 
cells by the modified preplate technique for the purpose of neuronal tissue engineering. The 
ability of the preplate technique to generate highly purified, although heterogeneous population 
of cells, in a large quantity from human muscle biopsies with minimal manipulations is 
extremely important since this will greatly facilitate clinical trials using autologous muscle 
biopsies for regenerative medicine. 
4.5 MATERIALS AND METHODS 
4.5.1 Cell isolation and culturing 
Using the modified preplate technique as previously described for mMDSCs (detailed in 3.5.1, 
and Appendix A), early and late preplate cell fractions human muscle-derived progenitor cells 
(hMDPCs) were isolated from four human skeletal muscle biopsies (mean age 27.3 years; range, 
21 to 72 years) obtained from the National Disease Research Interchange (NDRI). The fraction 
of the slowly adhering cells (SACs) containing hMDPCs was considered as human counterparts 
to mouse PP6 and was used throughout the study.  
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4.5.2 Real-Time PCR analysis 
Total RNA was extracted from 1x105 cells using Nucleospin RNA kit (Clontech Laboratories). 
cDNA was synthesized with SuperScriptTM II reverse transcriptase (Invitrogen), according to 
manufacturer’s instructions. PCR was performed with Taq polymerase (Invitrogen) per 
manufacturer’s instructions for 35 cycles at 58°C annealing temperature and PCR products were 
electrophoresed on 1% agarose gels.  The cDNA and primers, listed in Appendix B under Table 
B.1, were added to SYBR green PCR master mix (Applied Biosystems) according to 
manufacturer’s instructions. Each set of oligonucleotides was designed to spam two different 
exons to avoid genomic DNA contamination. Results are expressed relatives the housekeeping 
gene Cyclophlin. The assays were carried out in triplicates. All target genes were normalized to 
18S used as an internal control. The data were normalized to values obtained from 
undifferentiated cells.   
4.5.3 Immunocytochemistry 
Fraction of SACs containing the hMDPCs (pre- and post-differentiation) isolated from four 
individual donors were screened according to the detailed methodology in Chapter1 (section 
3.5.5) for several neuronal (Nestin, NeuN, NF, β-tubulin III, and MAP2ab), glial and Schwann 
cell-specific markers (CNPase, GFAP, p75, S-100), immature oligodendrocyte marker (NG2), 
mature oligodendrocyte marker-O4 [O4]), and a high affinity receptor for nerve growth factor 
(TrkA) by immunocytochemical staining.  
hMDPCs were detected using human specific marker lamin A/C. Cells were incubated 
with mouse anti lamin A/C (1:200; Vector) combined with all the antibodies listed above except 
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for the ones developed in mouse to avoid cross reactivity at 4°C overnight. The next day, the 
cells were rinsed with PBS and incubated with biotinylated anti-mouse IgG (1:200; Vector) for 1 
h at room temperature, and subsequently stained with streptavidin-conjugated 488 (for lamin 
A/C immunostaining, 1:500; Vector) for 20 min. hMDPCs were then exposed to the following 
secondary antibodies to the appropriate species: donkey anti-mouse IgG-AlexaFluor® 594- or 
488-conjugated (1:500; Molecular Probes), donkey anti-rabbit IgG-AlexaFluor® 594- or 488-
conjugated (1:500; Molecular Probes) for 30 min, and Cy3-conjugated anti-goat IgG (1:1000; 
Sigma-Aldrich) against nestin antibody for 1 h. To visualize the nuclei, the cultures were then 
incubated with DAPI (4′, 6′ diamidino-2-phyenylindole, 100 ng/ml; Sigma-Aldrich) for 10 
minutes. Culture slides (BD Falcon™) were mounted with Vectashield® medium (Vector). 
Bright-field and fluorescent images were taken using a Nikon Eclipse E800 microscope equipped 
with a Q imaging Retiga Exi digital camera or Leica DMIRB microscope equipped with a Q 
imaging Retiga digital camera both running with the Northern Eclipse software system (v. 6.0; 
Empix Imaging, Inc.). Cells were systematically quantified in at least 15 fields across the slides, 
or wells of culture dishes from four to six independent experiments and the ratio of positive 
nuclei to the total nuclei defined the percent positive cells. Negative control culture wells were 
similarly processed but without primary antibodies. To control for nonspecific binding, some 
wells were processed with normal mouse or rabbit IgG and followed by the same secondary 
antibodies. 
4.5.4 Cell transplantation 
All procedures were performed according to the University of Pittsburgh Institutional Animal 
Care and Ethics Committee with approved protocol (13-03). Four to five-millimeter segment of 
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sciatic nerve from 6- to 8-week-old SCID mice (C57BL/6J-Prkdcscid/SzJ; Jackson Laboratory) 
was removed resulting in a ~6.5- to 7-mm defect due to retraction of the nerve ends. Immediately 
thereafter, a viable single cell suspension of 3x105 SAC containing hMDPCs isolated from 
human donors, or an equal volume (15 μL) of PBS (control), was injected into proximal and 
distal nerve stumps. Mice from each group were sacrificed 6 and 12 weeks after transplantation, 
and the hind limbs, including the sciatic nerve, were harvested, flash frozen in 2-methylbutane 
pre-cooled in liquid nitrogen, serially sectioned in 6 μm thickness, and stored at -80 °C for 
further analysis.  
4.5.5 Immunohistochemistry 
Cryosections of the hind limb were first immunostained for FluoroMyelin red (Molecular 
Probes) according to the protocol provided by the manufacturer, and then fixed in 4% PFA 
blocked with 5% DS for 1 h, and incubated with rabbit anti-NF (1:300, Chemicon) for 2 h at 
room temperature. The tissues were then rinsed with PBS and stained with donkey anti-mouse 
IgG-AlexaFluor® 488-conjugated for 20 min. In addition, the regenerated sciatic nerves were 
cryo-sectioned longitudinally, fixed with 5% formalin, blocked with 10% GS, and incubated 
overnight at 4°C with both rabbit anti-NF (1:300; Chemicon) and mouse anti-CNPase (1:200; 
Sigma-Aldrich) antibodies. The next day, the sections were rinsed with PBS and incubated with 
biotinylated anti-mouse IgG (1:200; Vector) for 1 h, and subsequently stained with streptavidin-
conjugated Cy3 (for CNPase immunostaining, 1:500; Sigma-Aldrich) at room temperature for 20 
min. Sections were then exposed to donkey anti-rabbit IgG-AlexaFluor® 488-conjugated (1:500; 
Molecular Probes) for 20 min to immunostain for NF-positive axons.  
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For human cell survival and colocalization study, the fixed sections were blocked with 
5% GS and incubated with human anti-human PCNA (Proliferating Cell Nuclear Antigen, 1:500; 
US Biological) for 45 min. Sections were rinsed with PBS and exposed to goat anti-human IgG-
AlexaFluor® 555-conjugated (1:500; Molecular Probes) for 15 min. Sections were then 
incubated with rabbit anti-GFAP (1:500; Chemicon) for 3 h at room temperature, rinsed with 
PBS, and exposed to donkey anti-rabbit IgG-AlexaFluor® 488-conjugated (1:500; Molecular 
Probes) for 20 min. Nuclei were revealed with DAPI. For all the above procedures, negative 
control sections were similarly processed but without primary antibodies or with normal mouse 
or rabbit IgG in replacement for secondary antibodies to control for nonspecific bindings. 
4.5.6 Morphometric analysis of the regenerated nerve 
Morphometric characteristics of 300-500 fibers in mid-sections of regenerated nerve were 
evaluated using toluidine blue and electron microscopy images. Number of myelianted axons, 
myelin thickness, cross-sectional area of myelianted axons, and g-ratio were measured and 
analyzed following the same protocols as previously described in methodology section of 
Chapter 1 (3.5.9).  
4.5.7 Functional assessment 
We used our previously established walking track model to evaluate functional recovery of mice 
implanted with hMDPCs versus PBS during 14 weeks interval (2,4,8,12, and 14weeks)  post-
operation.  Measuring factors were quantified from mice foot prints and used to calculate SFI 
following same methodology as previously described in Chapter 1 (3.5.10) and Appendix C. 
 79 
4.5.8 Statistical analysis 
Statistical analysis was carried out using SigmaStat (Jandel Scientific v2.0) software package. 
Morphometric parameters are expressed as the median values, 25th-75th percentiles. Direct 
comparisons between treatment and control groups for myelianted fiber counts data was 
analyzed using One-way ANOVA. However, the data for the myelin thickness, myelinated fibers 
area, axon area, and g ratio violated the assumptions of normality and variance and these were 
compared using Kruskal-Wallis One-way ANOVA on ranks. If statistical difference was observed, 
Tukey Test was performed using All Pairwise Multiple Comparison Procedures to isolate the group 
or groups that differ from the others. One-way ANOVA or the Kruskal-Wallis One-way ANOVA on 




5.0  DIRECT CONTRIBUTION OF VASCULAR-ENDOTHELIAL CELLS FROM 
VENOUS GRAFTS SUPPORTS PERIPHERAL NERVE REGENERATION 
5.1 INTRODUCTION 
Vein wrapping and vein grafts, as non-nervous conduits, have been effective alternative 
treatments of peripheral neuropathy in both experimental and clinical settings [40, 205-210]. The 
results of these studies and others have also shown improvement of the nerve function and the 
symptoms associated with recurrent compressive peripheral neuropathy [207-214], carpal tunnel 
syndrome [207, 215], tarsal tunnel syndrome [212], prevention of scar formation [213, 216, 217], 
and alleviation of painful neuroma [218, 219] in clinical settings. However, little is known at 
present about the mechanisms that mediate the observed improvement. Recently, a vascular 
niche for adult hippocampal neurogenesis was identified [220]. Endothelial cells are recognized 
as a critical component of the neural stem cell niche, as they secrete factors that maintain the 
self-renewal and multipotency of neural stem cells [134]. Our group has recently isolated a 
vascular-endothelial cell population form human biopsies, which express both myogenic and 
endothelial cell markers and possess superior multipotency, regenerative abilities and resistance 
to oxidative stress when compared with myogenic or endothelial fractions [135]. The description 
of multipotent myoendothelial cells in human skeletal muscle and pericytes throughout the 
organism [135, 136] supported our hypothesis that the healing of peripheral nerves is mediated 
by vascular cells from venous grafts.  
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To test our hypothesis, we used femoral veins obtained from donor (male) rats as 
conduits to bridge peripheral nerve defects created in the femoral nerves of host (female) rats. 
The possibility that vascular cells residing in the blood vessel can contribute in the process of 
nerve regeneration was assessed using fluorescence in situ hybridization (FISH) to detect donor-
derived Y chromosomes co-localized with Schwann cells nuclei of host regenerated nerve in our 
sex-mismatch model. To further verify our hypothesis, we altered the course of cell contribution 
from donor venous grafts by decellularization (complete cell removal) and irradiation 
(preventing cell proliferation and migration). A sustained decrease in nerve regeneration in 
decellularized or irradiated groups would be an appropriate indicator if active participation of 
migrated cells is essential. Proper organization and remyelination of axons and level of scar 
formation was assessed by histology and immunohistochemistry. Morphometric parameters were 
quantitatively measured in the mid-section of the regenerated nerves using toluidine blue and 
electron microscopy images. Results from this study may uncover valuable information to 
explain the cellular basis for success of using vein wrapping as an effective clinical treatment for 
peripheral nerve injuries. 
5.2 RESULTS 
5.2.1 Migration and proliferation in vein grafts are inhibited following irradiation 
To determine the effect of decellularization or irradiation on venous grafts before transplantation, 
pieces (~1–2 mm) from intact (control), decellularized, and irradiated veins were placed in 
fibronectin-coated 24-well plates in endothelial cell growth medium (EGM-2, n = 3). While 
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many cells had migrated out of the vein at 7 days in culture (Figure 5.1a), no migrating cells 
were detected out of the irradiated veins (Figure 5.1a) in parallel cultures. Cells were still visible 
at the edges of the intact and irradiated veins after 14 days of culture (Figure 5.1b, arrows), and 
continuously outgrew from the explants (Figure 5.1b, arrowheads) as a mixture of endothelial 
cells, vascular smooth muscle cells, and pericyte progenitors (Figure 5.1c). Human endothelial 
cells fail to replicate after a 1000-rad irradiation [221]. We have assessed doses of 1000, 2000, 
5000, and 10,000 rad. The 1000-rad was chosen because it limits the cell damage while 
preserving the integrity of vein grafts. The viability of clustered cells attached to the irradiated 
veins was verified using the MTT assay. Presence of purple cells suggests that mitochondrial 
dehydrogenase enzyme from these viable cells cleaved the tetrazolium ring, resulting in 
accumulation of impermeable purple formazan crystals. Though the cells appeared to be viable 
(Figure 5.1c, purple), the cells could not migrate out of the vein even after 25 days, proving that 






Figure 5.1: Migration and proliferation of the cells are inhibited following irradiation 
The pieces (1-2 mm) from intact and irradiate veins were separately cultured in wells of 24 well plate 
coated with fibronectin in EGM2, an endothelial growth medium. (a) Many cells were outgrown from the 
intact vein at 7 days in culture, while no cells were visible in the irradiated vein. (b) Fourteen days post-
culture, cells were still visible at the edges of the intact and irradiated veins (arrows), and continuously 
outgrown only from the intact vein (arrowheads). (c) Cells outgrown from the intact vein were showed a 
diverse morphology, while cells in the irradiated vein stayed as clusters and could not migrate out of the  
even after 25 days of being in the culture dish but were viable verified by using the MTT assay (purple). 
Data represent at least three independent experiments. Scale bars represent 200 μm (a) or 100 μm (b and 
c).  
 
Similar to previous work reported by Schaner et al. [222], treating the venous grafts with 
SDS resulted in cell disappearance throughout the tissue while preserving matrix integrity. We 
did not observe cells on the dish containing the decellularized vein (Figure 5.2). 
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 Figure 5.2: Vein rendered acellular with SDS has well-preserved matrix for grafting  
Light microscopy of venous graft after treatment with 0.075% SDS revealing preservation of extracellular 
matrix but disappearance of cells throughout the treated tissue. Scale bar represent 100 μm. 
5.2.2 Cells from venous grafts contribute in nerve regeneration 
Peripheral nerve lesions were bridged using venous conduits in a rat sex-mismatch model, and 
fluorescence in situ hybridization (FISH) was used for detecting donor-derived Y chromosomes 
in regenerated nerves. A segment of the femoral vein separated from artery and nerve 
compartment of a male rat was used as a conduit to bridge femoral nerve defect made in female 





Figure 5.3: Surgical procedure for isolation and implantation of venous graft 
(a) Five to six millimeters segment of pure femoral vein from a male Fisher rat was isolated, pulled over a 
0.2-mm forceps (vessel dilator) and placed in sterile PBS for later use. (b) The right femoral nerve from a 
female rat was exposed, and a 5-mm segment of peripheral nerve was carefully separated so as not to 
disturb the attached artery and vein compartment. Using surgical scissors, a cut was made in the middle of 
the femoral nerve of a female Fisher rat to create two ends. (c) The distal end of the femoral nerve was 
grabbed by the forceps carrying the previously removed male-derived vein. One millimeter of the distal 
end was cut later to have a fresh end. (d) Using 10/0 monofilament nylon, the proximal and distal stumps 
was drawn together and tied to form a loop while keeping a gap of ~3-mm. Every effort was made to 
avoid tension and correct rotational alignment throughout. (e) Using the forceps, the femoral vein was 
pulled over the gap toward the proximal end of the nerve like a glove. The vein graft was interposed 
between ends of the femoral nerve with 10/0 monofilament nylon, using 2–3 epineurial stitching for each 
stump.   
 
Proper nerve regeneration four–six weeks after implantation was assessed using 
histochemistry, immunohistochemistry, and electron microscopy. At the time of harvesting, the 
vein grafts could be identified under the operating microscope in all the groups without any sign 
of absorption or degeneration. Minimal scar or adhesions were noticed between the nerve and the 
vein graft, although some scarring was evident in recipient of irradiated veins. Complete femoral 
nerve regeneration was observed in all of the rats that received intact control vein grafts, while 
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the recipient of decellularized and irradiated veins exhibited only minimal regeneration. Four–six 
weeks after transplantation, Masson’s trichrome stain of regenerated nerves in decellularized and 
irradiated grafts (Figure 5.4a) showed lower myelinated axons regeneration (no traces of pink 
stain) and more collagen deposition (intense blue stain), as compared to nerves in intact grafts. 
The regenerated nerve in intact venous grafts showed a well-organized architecture of 
myelinated nerve fibers, including less fibrotic tissue (collagen, blue) between fascicles 
(epineurium) and within individual axons (endoneurium) (Figure 5.4a). Regenerated nerves in 
intact grafts exhibited many neurofilament-positive axons (green) surrounded with myelin sheets 
positive for fluoromyelin (red), as compared to other experimental groups (Figure 5.4b), 
suggesting proper formation of mature myelinated axons at the site of nerve regeneration. This 







Figure 5.4: Intact venous grafts exhibit more effective nerve regeneration 
(a) Eight weeks post-transplantation, Masson’s trichrome staining revealed absence of collagen matrix 
and adventitia of the grafted vein (blue) and defined nerve regeneration with perineurium surrounding the 
nerve bundles (pink) in intact graft, while thickening of the extracellular matrix and disorganized 
perineurium was obvious in decellularized and irradiated grafted groups. Undamaged host artery shown 
with arrowheads is used as reference point. (b) the cross-section of the regenerated nerve exhibited 
regenerated NF-positive axons (green) encompassed by fluoromyelin-positive Schwann cells (red) 
suggesting proper regeneration of the femoral nerve in intact control grafts compare to treatment groups. 
Scale bars represent 100 μm.  
 
Toluidine blue staining (Figure 5.5a), and transmission electron microscopy (TEM) 
images of the same sections (Figure 5.5b) revealed that the decellularized and irradiated veins 
induced only scattered regeneration in form of small axons with thin myelin sheets and more 
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prominent thickening of the extracellular matrix when compared to intact venous grafts (Figure 




Figure 5.5: Intact venous grafts show proper regeneration and myelination 
(a) Toluidine blue staining and (b) transmission electron microscopy at the mid-proximal sections 
confirm superior regeneration with larger myelianted axons including presence of myelin-producing 
Schwann cells (arrows) surrounding the regenerated axons and absence of connective tissue fibrosis in 
transplanted intact grafts while both treated grafts showed poor level of nerve regeneration evident with 
small myelinated Schwann cells and high level of connective tissue fibrosis indicated by collagen. “Sc” 
corresponds to Schwann cells, “M” to myelin sheath, “Ax” to axon, and “Col” to collagen. Scale bars 
represent 100 μm (a) or 10 μm (b). 
 
Morphometric parameters such as number of myelinated axons, myelin thickness, 
myelinated fiber area, axon area, and g-ratio (axon area : myelinated fiber area) [148] were 
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quantitatively measured in the mid-section of the regenerated nerves using toluidine blue and 
TEM images (Table 1). Eight–ten weeks after transplantation, number of the regenerated 
myelinated axons were not significantly different between the treatment groups and when 
compared to the intact femoral nerve. Although, there were clearly larger and thicker myelinated 
axons in uninjured control nerves and nerves treated with intact vein grafts, compared to nerves 
associated with decellularized and irradiated vein grafts. Therefore, axonal cross-sectional area 
and myelin thickness were assessed as a measure of regenerating fiber maturation. Median 
values for myelinated fiber area and myelin thickness in decellularized and irradiated graft 
groups were significantly smaller than in the intact grafts. Although, intact grafts showed better 
myelination, the values did not reach the level of the uninjured control nerves. The median 
axonal area and the g-ratio, which describes the relationship between axon caliber and 
myelinated fiber caliber, were significantly smaller in decellularized or irradiated vein compared 
to intact grafts and control femoral nerves. The low g-ratio in nerves decellularized or irradiated 
veins is due in part to the shrinkage of axons and their failure to regain their normal diameter 
[223], and the presence of more regenerated fibers with thin myelin sheaths compared to nerves 
treated with intact veins and uninjured control nerves. In contrast, no significant difference was 
seen in the median axonal area and g-ratio between the intact grafts and uninjured control nerves, 
suggesting that intact venous grafts contributed considerably to nerve regeneration. 
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Table 5.1: Morphometric analysis of regenerated myelianted axons 
Median values for the number of the myelinated axons (per 10,000 μm2) at the mid-proximal portion of 
the regenerated nerve stained with toluidine blue showed no significant difference between the groups (P 
= 0.760; ANOVA, Kruskal-Wallis on Ranks). Parametric analyses of transmission electron microscopy 
images of the proximal-mid cross-sections of the regenerated femoral nerves show that median (25th–75th) 
values of the myelianted fiber area and myelin thickness were statistically differ between the groups (*P 
< 0.05; ANOVA, Kruskal-Wallis on Ranks) when compared to control femoral nerves (§ P < 0.05; 
ANOVA, Kruskal-Wallis on Ranks). The quantitative measurement of axon area and g-ratio (axon area : 
myelinated fiber area) showed no difference between the intact graft and control femoral nerves. The 
decellularized and irradiated groups showed significantly lower g-ratio associated with thinner axonal 
remyelination when compared to intact grafts (*P < 0.05, ANOVA, Kruskal-Wallis on Ranks) and control 




Supporting the hypothesis that cells residing in the blood vessel wall participate in the 
process of myelination, colocalization of Y chromosomes-Cy3 (red) with Schwann cell nuclei of 
the host (DAPI, blue) revealed the possible fusion of donor cells with host glial cells (Figure 
5.6a, arrows). FISH analysis on positive control section of male rat confirmed high level of 
probe sensitivity, specificity, and hybridization efficiency (Figure 5.6b, arrows). Hence, to 
further examine if the direct contribution of cells play a major role in the regeneration process, 
decellularized and irradiated vessels were used simultaneously with intact venous grafts. Four–
six weeks after injury, FISH against Y chromosome verified the contribution of male-derived 
donor blood vessel progenitor cells with female host Schwann cells nuclei in regenerated nerves 
of intact venous grafts, but not in decellularized or irradiated grafts. Thus cells residing in the 





Figure 5.6: Donor blood vessel cells from venous grafts actively participate in nerve regeneration  
(a) Four-six weeks after injury, FISH against Y chromosome verified the active contribution of male-
derived donor blood vessel progenitor cells (Y chromosome-Cy3 positive nuclei) in the regenerated 
female femoral nerve (host Schwann cells nuclei counterstained with DAPI are shown by arrows, n = 6). 
(b) detection of Y chromosome signals in almost all of the nuclei of positive control tissues obtained from 
male rat revealed high specificity of the chosen probe. Chromosome 12-FITC probe is used as a reference 
chromosome to check for the hybridization efficiency. Scale bars represent 100 μm.   
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5.3 DISCUSSION 
Our sex-mismatch venous graft model reveals active contribution of stem/progenitor cells that 
migrate from the venous nerve guide to the site of nerve injury and accelerate the process of 
remyelination and regeneration. This was evidenced by the presence of donor-derived Y 
chromosomes in regions of regenerated nerve that were co-localized with Schwann cell nuclei of 
the host. The proper nerve regeneration and reduced endoneurial scarring shown by intact venous 
grafts may be due on the one hand to Schwann cell motility, that facilitate graft invasion [67], 
but also to decrease in fibroblast infiltration [224], prevention of uncontrolled fiber outgrowth 
[225] and neuroma formation [218, 219], improved gliding on the smooth inner surface of the 
vein [208, 216], and scarring prevention [213]. Neovascularization [212, 215] and growth factor 
secretion [225] are suggested to be involved in facilitating the process of nerve regeneration 
using venous conduits.  Notably, vein decellularization, which destroys the residing cells while 
the mechanical properties of the vessel are not impaired [226], and irradiation, that causes cell 
depletion and prevents cell replication and migration [221, 227] severely compromised nerve 
regeneration. Collectively these experiments provide evidence that without direct involvement of 
cells, the nerve regeneration mediated by vein wrapping is limited. 
The efficacy of a venous nerve conduit for reconstruction of a peripheral nerve likely 
relies on many factors, for instance the secretion of cytokines by donor and/or host cells, 
recruitment of host Schwann cells to promote regeneration, and improvement of angiogenesis.  
Here we provide evidence that blood vessel wall derived cells migrate and contribute to 
myelination by way of fusion or differentiation into Schwann cells. As almost all issues are 
vascularized, the walls of blood vessels are emerged as a possible reservoir of ubiquitous multi-
lineage cells that could be recruited in emergency situations or when tissue-specific progenitors 
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have been exhausted. This concept has been largely emerged by description of mesoangioblasts 
and hematopoietic stem cells [228, 229]. More recently, adipose vasculature has been identified 
as a niche where white fat progenitor cells reside [230]. The notion that myoendothelial cells 
and/or pericytes are likely at the origin of muscle derived stem cells was the conclusion of our 
previous study and is further supported by the current study [135, 136], indicating that venous 
nerve conduits may promote nerve repair through similar populations of cells. Future 
experimentation will be needed to distinguish which types of blood vessel-derived cells are the 
key players in such a process. It is noteworthy that combine muscle-vein nerve guides have 
shown promising results for larger nerve defects regeneration [38, 231-233]. Clinical application 
of muscle-vein-combined grafting led to efficient nerve repair, both for motor and sensory 
nerves, with satisfactory functional recovery in 85% of the patients [38]. Muscle tissues used to 
fill up the vein graft, contain satellite cells, myoendothelial cells, and pericytes that may migrate, 
proliferate, and differentiate toward the glial lineage thus promoting axonal growth and nerve 
regeneration. 
5.4 CONCLUSIONS 
In conclusion, this study establishes that blood-vessel-derived cells residing in the wall of venous 
grafts contribute in the process of peripheral nerve repair by way of migration, and cell fusion 
and/or differentiation. Presences of donor-derived Y chromosomes in the region of host 
regenerated nerve prove migration of vascular cells to the area of injury. This finding is validated 
by showing a sustained decrease in nerve regeneration by decellularization or irradiation of the 
venous grafts. Co-localization of Y chromosomes with host Schwann cells’ nuclei indicate that 
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nerve repair through vein grafting is mediated at least in part by vascular cells. Here, we 
uncovered valuable information to understand mechanisms underlying therapeutic benefits of 
using venous grafts as a nerve guide in clinic. We believe these results provide a cornerstone for 
future work intended to explore the relationship between stem/progenitor cells, cell fusion and/or 
differentiation, and nerve regeneration.  
5.5 MATERIALS AND METHODS 
5.5.1 Vein decellularization, and irradiation procedure 
With the aid of an operating microscope (WILD M690, WILD HEERBRUGG, Switzerland), 
segment of pure femoral veins were isolated and decellularized according to a protocol 
previously reported by Shaner et al. [222]. Briefly, isolated femoral veins were placed into 
0.075% sodium dodecyl sulfate (SDS; Bio-Rad Laboratories) in PBS for 15 h at 37°C in a 
shaking water bath. Subsequently, they were rinsed by agitation in PBS at 37°C for 15 min 
repeatedly for five times. This method of decellularization has been confirmed to remove >94% 
of cells from the treated vein. For irradiation study, the grafts were irradiated at 1000-rad (4.4 
min) dose.  
5.5.2 MTT assay 
MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay,  was carried out to 
evaluate the cell viability [234]. Sterile solution of MTT (5 mg/ml stock, Sigma) was added to 
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the culture dishes (0.1 ml/ml media) containing control and experimental venous grafts and 
incubated for 60 min at 37°C. Mitochondrial dehydrogenase enzyme from viable cells cleaves the 
tetrazolium rings of the pale yellow MTT and form purple formazan crystals which is 
impermeable to cell membranes, thus resulting in its accumulation within healthy cells. Presence 
of purple color was detected and captured using a Leica DMIRB microscope equipped with a 
Retiga 1300 digital camera (Q imaging) and Northern Eclipse software system (v. 6.0; Empix 
Imaging, Inc.). 
5.5.3 Isolation and transplantation of venous nerve guide 
Surgical procedures were carried out according to protocol (13-03) approved by the University 
of Pittsburgh Animal Care and Use Committee. Female Fischer 344 rats weighing 100-125 
grams and male Fischer 344 rats weighing 200-225 grams were obtained from Harlan 
(Indianapolis, IN). With the aid of an operating microscope (WILD M690, WILD 
HEERBRUGG, Switzerland), 5- to 6-mm segment of pure femoral vein from a male Fisher rat 
was isolated, pulled over a 0.2-mm forceps (vessel dilator), and placed in sterile saline solution 
for later use. The right femoral nerve from a female rat was exposed, and a 5-mm segment of 
peripheral nerve was carefully separated so as not to disturb the attached artery and vein 
compartment.  Using surgical scissors, a cut was made in the middle of the femoral nerve of a 
female Fisher rat to create two ends. The distal end of the femoral nerve was grabbed by the 
forceps carrying the previously removed male-derived vein. Note that 1-mm of the distal end 
was cut later to have a fresh end. Using 10/0 monofilament nylon, the proximal and distal stumps 
was drawn together and tied to form a loop while keeping a gap of ~3–4 mm. Every effort was 
made to avoid tension and correct rotational alignment throughout. Using the forceps, the 
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femoral vein was pulled over the gap toward the proximal end of the nerve like a glove. The vein 
graft was interposed between ends of the femoral nerve with 10/0 monofilament nylon, using 2–
3 epineurial stitching for each stump. A small knot with a silk suture was left on the muscle 
above the construct at the proximal and distal end to allow easy identification at the time of 
harvest and cryosectioning. A total of 35 rats were transplanted with vein grafts for sex-
mismatched study (24 intact grafts, 4 decellularized grafts, and 4 irradiated grafts) and 3 sex-
matched (used as negative control for FISH analysis). 
5.5.4 Fluorescence in Situ Hybridization (FISH)  
Venous graft cryosections (6 μm) were fixed in methanol : acetic acid (3:1), dehydrated by 70, 
80, 95, and 100% ethanol for 3 min each and then denatured in 70% formamide-2 × saline 
sodium citrate (SSC) at  69 ± 1 °C. Slides were then dehydrated as above and air dried.  
Following manufacture's protocol, directly-labeled fluorescence rat-specific Y-chromosome-Cy3 
and chromosome 12-FITC probes (Cambio) was applied to the target areas (sections marked 
with diamond scriber), covered with plastic coverslips, glued with rubber cement and incubated 
in a humidity chamber for 18–24 h at 37 °C. The next day, coverslips were pilled off from the 
sections and slides were washed with 2 × SSC for 5 min, followed by washes in 50% formamide-
2 × SSC (12-13 min), 2 × SSC (three times for 7 min) and 2 × SSC-Tween (2 min). All washes 
were done in 45 °C. Slides were subsequently counterstained with DAPI and were mounted with 
Vectashield® medium (Vector). The hybridized Y-chromosome-specific probe was detected 
under Nikon Eclipse E800 microscope equipped with a Retiga Exi digital camera and Northern 
Eclipse software system (v. 6.0; Diagnostic Instruments). Sections of hind limb from male rats 
 97 
served as positive control and were similarly processed to check for probe specificity and 
hybridization efficiency for Y chromosomes. Negative control tissues consisted of sex-matched 
venous grafts (female femoral vein transplanted over the female femoral nerve) to check for 
absence of the Y-chromosomes signals. 
5.5.5 Morphometric analysis of the regenerated nerve 
To evaluate the degree of myelination, reconstructed femoral nerves including all tissue 
surrounding them, were processed for light and transmission electron microscopy studies. The 
tissues were fixed in 2.5% glutaraldehyde (EM grade, Taab Chemical) in 0.1M phosphate buffer 
(pH 7.3; Fisher Scientific) overnight at 4°C. The contralateral sciatic nerve harvested at the same 
level served as a “normal” control. The nerves were then rinsed in PBS, post-fixed in 1% 
osmium tetroxide (Electron Microscopy Sciences) with 0.1% potassium ferricyanide (Fisher 
Scientific), dehydrated in a series of ethanol solutions (30% - 90%; Fisher, and 100% [Ethanol 
200 Proof]; Pharmco), exposed to propylene oxide twice for 10 min each and embedded in Epon 
(Dodecenyl Succinic Anhydride, Nadic Methyl Anhydride, Scipoxy 812 Resin and 
Dimethylaminomethyl; Energy Beam Sciences). All grafted segments were carefully oriented in 
order to obtain sections perpendicular to their long axis. Semi-thin (300 nm) sections were cut 
using a Lecia Ultracut and stained with 0.5% toluidine blue (Fisher Scientific) and examined 
under light microscope (Olympus BX51) with Magnafire 2.1A image capture software, and 
quantified for the number of the myelinated axons. Ultrathin sections (65 nm) at distal, mid, and 
proximal ends were obtained using a Leica Ultracut Microtome (Leica) and stained with 2% 
uranyl acetate (Electron Microscopy Sciences) and Reynold’s lead citrate (Fisher Scientific), and 
examined on a JEOL JEM-1011 transmission electron microscope in collaboration with Dr. 
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Simon Watkins (University of Pittsburgh, Pittsburgh, PA).  The number of myelinated axons in 
~10,000 μm2 of the cross-sectional area of the nerve was counted, and median area of myelin 
thickness, median cross-sectional area of myelinated axons, and g-ratio (axon area/myelinated 
fiber area) were examined in mid-sections. Each section was divided into four quarters. Each 
quarter of the nerve was analyzed individually, and morphometric parameters of 300-600 fibers 
were calculated using the Northern Eclipse software system (v. 6.0; Empix Imaging, Inc.) 
following image capture, background subtraction, image enhancement, automatic thresholding, 
and final editing. 
5.5.6 Statistical analysis 
Statistical analysis was carried out using SigmaStat (Jandel Scientific v2.0) software package. 
Morphometric parameters are expressed as the median values, 25th-75th percentiles. Direct 
comparisons between treatment and control groups for myelianted fiber counts data was 
analyzed using One-way ANOVA. However, the data for the myelin thickness, myelinated fibers 
area, axon area, and g ratio violated the assumptions of normality and variance and these were 
compared using Kruskal-Wallis one-way ANOVA on ranks. If statistical difference was observed, 
Dunn’s Method was performed using All Pairwise Multiple Comparison Procedures to isolate the 







6.0  DISSERTATION SYNOPSIS  
Here we described a population of stem cells isolated from post-natal skeletal muscle that can 
differentiate into muscle, neuron, and glial cells in vitro.  Transplantation of these cells into a 
critical-size sciatic nerve defect in mice greatly enhanced the rate of nerve regeneration, showing 
full restoration of sciatic nerve by promoting axonal regeneration via myelin-producing 
Schwann-like cells. Functional recovery was evident by improved walking pattern of cell-
transplanted mice after sciatic nerve injury indicating an enhancement in target organ 
reinnervation. Several weeks after complete regeneration of the sciatic nerve, neoplastic growths 
were observed. The resulting tumors were classified as malignant peripheral nerve sheath tumors 
with rhabdomyoblastic differentiation, expressing myogenic, neurogenic, and glial cell markers, 
common markers of human malignant Triton tumors. We observed that the neoplasias were 
composed almost entirely of donor cells, and cells isolated from the tumors were serially 
transplantable. We provide evidence that the stem cells used in this study were not oncogenic in 
nature, and displayed no sign of tumorigenesis 17 weeks post-implantation into the 
gastrocnemius muscles of mdx mice or 1 year following subcutaneous or intravenous injection. 
We postulate that the time- and microenvironment-dependent transformation observed here was 
due to donor cells receiving concomitant neurogenic and myogenic signals. Interestingly, further 
differentiation of the cells toward the neurogenic lineage prior to implantation abrogated the 
transformation.  
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The studies presented in Chapter 1 provide evidence that experiments in tissue 
engineering and regenerative medicine should be evaluated over a prolonged period of time, as 
the transformation observed here occurs only after 11 weeks post-implantation. We believe that 
an effective cell-based intervention therapy will rely on the better understanding of the 
interaction of transplanted cells with their environmental cues and critical aspects of risk versus 
benefit of using stem cells need to be further addressed. We consider our findings intriguing and 
anticipate that our results obtained using the murine cells in the process of peripheral nerve 
regeneration will constitute proof of concept, and will provide the foundation for future studies. 
In addition, our murine model of MTT may open new areas of investigation to elucidate 
underlying mechanism of transformation and can provide an opportunity for contribution from 
other investigators in several fields, including stem and cancer cell biology, regenerative 
medicine, and cancer therapeutics.  
Our aim in objective 2 was to determine whether progenitor cells isolated from human 
adult skeletal muscle using modified prelate technique differentiate toward neural/glial cell 
lineages in vitro, and, ultimately be applied in our sciatic nerve defect model in mice. As 
expected, hMDPCs were able to undergo myogenic differentiation and form multinucleated 
myotubes expressing f-MyHC under low-serum conditions. These cells were able to form 
neurospheres and terminally differentiated into all three ectodermal lineages, neuronal, astroglial 
and oligodendroglial, as well as peripheral nerve supporting cells, the Schwann cells. hMDPCs 
showed remarkable capacity to regenerate nerve and improved functional deficits upon 
transplantation into critical-size sciatic nerve defect model of mice. Histological and 
immunological analysis revealed that regenerated nerves contained many PCNA+ donor cells 
predominantly located in front and along the growing cone of the proximal end. Colocalization of 
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hMDPCs with GFAP and CNPase suggested possible differentiation of donor cells into glial 
lineage especially the Schwann cells. We believe these cells may present to be the counterpart to 
our murine MDSCs suggesting that human muscle tissue contain multipotent progenitor cells 
that could be directed to express or differentiate toward neuronal and glial phenotypes.  
The mechanism by which the MDSCs promoted the repair of the injured sciatic nerves 
remains unclear; however, the ability of the injected MDSCs to differentiate into Schwann cells 
may have contributed to these events. Schwann cells release various neurotrophic substances that 
are key regulatory proteins in the modulation of neuronal survival, axonal elongation, synaptic 
plasticity, and neurotransmission [71]. The fact that a large number of Schwann cells in the 
regenerated nerves were belong to the host suggests that the hMDPCs may have released factors 
that induced endogenous axonal growth and host Schwann cells proliferation. Much work 
remains to be done before applications based on these cells progress from bench to bedside, but 
the preliminary data reviewed above strongly suggest that the future use of the preplate technique 
to isolate cells for cell-based therapies for peripheral nerve is promising.   
Multi-lineage progenitor cells have been recently identified in blood vessel walls, notably 
in skeletal muscle, and venous grafts have been used effectively to bridge nerve defects 
experimentally and clinically, through unknown cellular mechanisms. According to the results in 
chapter 3, we introduced and provided evidence of another important factor that may explain the 
mechanism (s) underlying therapeutic benefits of vein wrapping in clinic. Previously we have 
touched up on few ideas that have been introduced to explain the reason behind the usefulness of 
this technique in clinic including: (i) the venous graft can be easily obtained from sites near the 
injury so that closer to it is not necessary to perform any new incisions at other sites, and 
secondary damage created by the withdrawal of healthy nerve is also avoided; (ii) the venous 
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graft walls, which appear to act as a barrier prevent ingrowths of fibrous scar tissue and 
dispersion of the regenerating nerve fibers, (iii) vein may also be a source of growth factors; and, 
(iv) capping the nerve stump with vein seems to be one of the most effective methods of 
neuroma prevention in clinical settings. Using a sex-mismatch model, we identified donor-
derived Y chromosomes co-localized with host Schwann cells’ nuclei, indicating that nerve 
repair through vein grafting is mediated by vascular cells. Migration of these cells to the site of 
injury helped to facilitate the process of remyelination and regeneration. Furthermore, a 
sustained decrease in nerve regeneration by decellularized or irradiated venous grafts also 
highlights the contribution of blood vessel-derived cells to nerve repair 
Collectively, the above findings encourages a new look at nerve repair by vein wrapping 
whereby cell migration from the vessel walls improve axonal in-growth. Also, neuronal and glial 
differentiation of progenitor cells isolated from mouse and human skeletal muscle further 




THE MODIFIED PREPLATE TECHNIQUE 
All stem/progenitor cells used throughout this study were isolated from mouse or human skeletal 
muscle using a modified preplate technique developed in the laboratory of Dr. Johnny Huard, 
reported in Qu-Peterson et al. [124], and revisited by Burhan et al. [142]. Biopsies were obtained 
from hind limbs of female neonatal C57BL/6J mice (Jackson Laboratory) or human skeletal 
muscle of 4 human donors obtained from the National Disease Research Interchange (NDRI). 
The muscle tissues were was minced and enzymatically digested in 0.2% collagenase-type XI 
(Sigma) for 1 h. After centrifugation, the cells were incubated in 0.3% dispase (2.4 units/ml of 
HBSS [Invitrogen]) for 30-45 min. They were then transferred to 0.1% trypsin-EDTA 
(Invirogen) for 30 min, centrifuged, re-suspended in proliferation medium (DMEM [Invitrogen] 
with 10% horse serum (HS [Invitrogen]), 10% fetal bovine serum (FBS [Invitrogen]), 1% 
penicillin-streptomycin [Invitrogen] and 0.5% chick embryo extract [Accurate Chemical and 
Scientific Corporation] and put into a dish coated with collagen Type I (Sigma). As seen in 
Figure A.1, some cells attach to first dish and those that do not are transferred to a new dish 2 
hours later. The cells found in the first dish are known as preplate 1 or PP1 and contain mostly 
fibroblastic cells. PP2 to PP6 are obtained by transferring the supernatant to new flasks every 24 
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hours. PP2 to PP5 are known as “early preplate” (EP) cells. Cells in the PP6 cell population took 
an additional 24–72 h to attach to collagen-coated dishes after transfer from PP5 and were 
termed “late preplate” (LP) cells. The LP cell culture was then sub-plated in a 12-well tissue 
culture dish. Most of the LTP cells died during the first 1–2 wks of the cultivation period, with 
very few of the adherent surviving cells proliferating and forming colonies that are called “long-
term proliferating” (LTP) cells. These cells were then called muscle-derived stem cells (MDSCs) 
based on their superior capacity for survival, self-renewal, and multilineage differentiation [124]. 
In case of human muscle-derived progenitor cells (hMDPCs), the fraction of the rapidly adhering 
cells (RACs) are considered as human counterparts to PP2–PP5 and slowly adhering cells 








SUPPLEMENTAL DATA FOR REAL-TIME PCR ANALYSIS 
All the primers used in study presented in Chapter 2 have been designed using the program 
found at http://frodo.wi.mit.edu/cgi-bin/primer3/ primer3_www.cgi and ordered from Integrated 
DNA Technologies. All the primers were designed specifically against human genes. The name, 
sequences, and aplicon position of the target gene primers are listed below in Table B.1.  
 





WALKING TRACK ANALYSIS 
Although the best method to evaluate the improvement of nerve function remains undiscovered, 
sciatic functional index (SFI) has shown to be a quantitative, non-invasive, and reliable method 
of tracking the regeneration capability, visible by the gait of the animal over time. SFI has been 
shown to have the highest correlation to nerve function [235], and is considered an assessment of 
overall nerve function because “walking requires complex motor-unit reinnervation coordination 
by cortically integrated sensory feedback” [236]. To calculate the SFI, walking tracks were first 
obtained using a 6 × 46 cm corridor (straight maze) lined with white paper (Benchkote; Cardinal) 
illuminated with a 50W lamp with an open end to a darkened compartment. The hind paws of the 
animals were pressed into the surface of a black waterproof inkpad. The animals were then 
walked multiple times to obtain measurable footprints over 14 weeks time period. The animals’ 
feet were immediately washed in lukewarm water at the end of the tests. The collected paw 
prints were scanned with a Microtek 9800XL scanner (Figure C.1). The investigators were 





Figure C.1: Pattern of postoperative mouse paw prints 12 weeks following transaction of the right 
sciatic nerve  
The narrowing of the toe spread and the elongation of the print length are greatly evident in PBS versus 




The tracks from FNr-MDSCs-treated, hMDPCs-treated, and PBS-treated groups were 
then evaluated for toe spread (TS, the distance between the first and the fifth toe) and print length 
(PL, the distance between the third toe and the heel) using the Northern Eclipse software system 
(Figure C.2). Factors were derived for each parameter by subtracting the values of post-
operative contralateral non-operated footprint (normal) from the right operated footprint 
(experimental) values and dividing by the normal values as previously described [237].  
Formula 1   
NTS
NTSETSTS −=factor   
NPL
NPLEPLPL −=factor  
In the above equations, ETS is the experimental toe spread (distance between 1st and 5th 
toes), NTS is the normal toe spread, EPL is the experimental print length (distance from the heel 
to the third toe), and NPL is the normal print length. These factors were incorporated into the 
equation derived by Bain et al. [237] for rats, and modified and validated by Inserra et al. [180, 
181] for mice, to calculate the sciatic functional index (SFI): 














Figure C.2: Representation of normal mouse footprint  
 
Of note, only TS and PL factors with their corresponding weighted coefficients, 
contributed to the mouse SFI formula (Formula 2). The values for the ITS factor were not 
statistically significant (P = 0.30) in our model, therefore, it was eliminated in our calculations.  
In fact, stepwise multiple linear regression by Inserr et al. [180] has also revealed very low 
correlation for ITS in their sciatic nerve transaction model, while changes in TS and PL were 
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